Back to products

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

Drug intermediates

Bio-reagents and biochemicals

MedKoo product information:

Gefitinib

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. Gefitinib (INN) (Iressa) is a drug used in the treatment of certain types of cancer. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts a growth factor in cancer cells. It is marketed by AstraZeneca and Teva. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

According to http://en.wikipedia.org/wiki/Gefitinib, Gefitinib is the first selective inhibitor of epidermal growth factor receptor's (EGFR) tyrosine kinase domain. Thus gefitinib is an EGFR inhibitor. The target protein (EGFR) is also sometimes referred to as Her1 or ErbB-1 depending on the literature source. EGFR is overexpressed in the cells of certain types of human carcinomas - for example in lung and breast cancers. This leads to inappropriate activation of the anti-apoptotic Ras signalling cascade, eventually leading to uncontrolled cell proliferation. Research on gefitinib-sensitive non-small cell lung cancers has shown that a mutation in the EGFR tyrosine kinase domain is responsible for activating anti-apoptotic pathways.  These mutations tend to confer increased sensitivity to tyrosine kinase inhibitors such as gefitinib and erlotinib. Of the types of non-small cell lung cancer histologies, adenocarcinoma is the type that most often harbors these mutations. These mutations are more commonly seen in Asians, women, and non-smokers (who also tend to more often have adenocarcinoma). Gefitinib inhibits EGFR tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR tyrosine kinase in activating the Ras signal transduction cascade is inhibited, and malignant cells are inhibited.

Gefitinib is currently only indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have previously received chemotherapy. While gefitinib has yet to be proven to be effective in other cancers, there is potential for its use in the treatment of other cancers where EGFR overexpression is involved.  In 2004, AstraZeneca informed the United States Food and Drug Administration (FDA) that a large randomized study failed to demonstrate a survival advantage for gefitinib in the treatment of non-small cell lung cancer (NSCLC). Whether progression-free survival is prolonged is not clear from this statement. AstraZeneca also withdrew their application to market gefitinib in Europe shortly after this announcement.

Erlotinib is another EGFR tyrosine kinase inhibitor that works in the same way as gefitinib. Given the lack of survival advantage for gefitinib and the positive results for erlotinib, erlotinib has replaced gefitinib in the United States (except in patients where gefitinib has had a proven response).

  1: Oxnard GR, Miller VA. Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park). 2010 Apr 30;24(5):392-9. Review. PubMed PMID: 20480735.

2: Neal JW, Sequist LV. First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. Clin Adv Hematol Oncol. 2010 Feb;8(2):119-26. Review. PubMed PMID: 20386533.

3: Funato T, Takeda M. [Current update and testing procedures for genetic diagnosis in malignant neoplasm: additional information on pathological tests]. Rinsho Byori. 2010 Feb;58(2):169-74. Review. Japanese. PubMed PMID: 20229816.

4: Provencio M, Sánchez A, Garrido P, Valcárcel F. New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin Lung Cancer. 2010 Mar 1;11(2):91-7. Review. PubMed PMID: 20199974.

5: Glynne-Jones R, Mawdsley S, Harrison M. Cetuximab and chemoradiation for rectal cancer--is the water getting muddy? Acta Oncol. 2010 Apr;49(3):278-86. Review. PubMed PMID: 20180626.

6: Guiu S, Coudert B, Favier L, Arnould L, Fumoleau P. [Management of metastatic

HER2-positive breast cancer: present and future]. Bull Cancer. 2010 Mar;97(3):365-83. Review. French. PubMed PMID: 20176546.

7: Rosell R, Morán T, Carcereny E, Quiroga V, Molina MA, Costa C, Benlloch S, Tarón M. Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. Clin Transl Oncol. 2010 Feb;12(2):75-80. Review. PubMed PMID: 20156777.

8: Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology. 2009;77(6):400-10. Epub 2010 Feb 2. Review. PubMed PMID: 20130423.

9: Gazdar AF. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev. 2010 Mar;29(1):37-48. Review. PubMed PMID: 20127143.

10: Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.

Cancer Metastasis Rev. 2010 Mar;29(1):49-60. Review. PubMed PMID: 20108024.

11: Wollenberg A, Kroth J, Hauschild A, Dirschka T. [Cutaneous side effects of EGFR inhibitors--appearance and management]. Dtsch Med Wochenschr. 2010 Jan;135(4):149-54. Epub 2010 Jan 25. Review. German. PubMed PMID: 20101558.

12: Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a

systematic review. J Thorac Oncol. 2010 Feb;5(2):260-74. Review. PubMed PMID: 20101151.

13: Inamura K, Ninomiya H, Ishikawa Y, Matsubara O. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med. 2010 Jan;134(1):66-72. Review. PubMed PMID: 20073607.

14: Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res. 2010 Apr 15;316(7):1083-100. Epub 2010 Jan 11. Review.

PubMed PMID: 20064507.

15: Minniti G, Muni R, Lanzetta G, Marchetti P, Enrici RM. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009 Dec;29(12):5171-84. Review. PubMed PMID: 20044633.

16: Selvaggi G, Scagliotti GV. Histologic subtype in NSCLC: does it matter? Oncology (Williston Park). 2009 Nov 30;23(13):1133-40. Review. PubMed PMID: 20043461.

17: Mok T, Wu YL, Zhang L. A small step towards personalized medicine for non-small cell lung cancer. Discov Med. 2009 Dec;8(43):227-31. Review. PubMed PMID: 20040275.

18: Lacroix L, Besse B, Bidart JM, Bosq J. [KRAS status versus EGFR status in lung cancer therapy]. Bull Cancer. 2009 Dec;96 Suppl:S75-83. Review. French. PubMed PMID: 20034873.

19: Mitsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol. 2010 Feb;40(2):101-6. Epub 2009 Dec 23. Review. PubMed PMID: 20031962.

20: Eck MJ, Yun CH. Structural and mechanistic underpinnings of the differential

drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta. 2010 Mar;1804(3):559-66. Epub 2009 Dec 22. Review. PubMed PMID: 20026433; PubMed Central PMCID: PMC2859716.

21: Wong ST. Emerging treatment combinations: integrating therapy into clinical practice. Am J Health Syst Pharm. 2009 Dec 1;66(23 Suppl 6):S9-S14. Review. PubMed PMID: 19923318.

22: Heukamp LC, Büttner R. [Molecular diagnostics in lung carcinoma for therapy stratification]. Pathologe. 2010 Feb;31(1):22-8. Review. German. PubMed PMID: 19997736.

23: Harichand-Herdt S, Ramalingam SS. Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women. Semin Oncol. 2009 Dec;36(6):572-80. Review. PubMed PMID: 19995649.

24: Rosell R, Viteri S, Molina MA, Benlloch S, Taron M. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol. 2010 Mar;22(2):112-20. Review. PubMed PMID: 19949333.

25: Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):713-22. Review. PubMed PMID: 19942148.

26: Carter CA, Kelly RJ, Giaccone G. Small-molecule inhibitors of the human epidermal receptor family. Expert Opin Investig Drugs. 2009 Dec;18(12):1829-42. Review. PubMed PMID: 19938898.

27: Akiyama T, Dass CR, Choong PF. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther. 2009 Dec;8(12):3173-80. Epub . Review. PubMed PMID: 19934277.

28: Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor

development: EGFR gene and cancer. FEBS J. 2010 Jan;277(2):301-8. Epub 2009 Nov 18. Review. PubMed PMID: 19922469.

29: Okamoto I. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J. 2010 Jan;277(2):309-15. Epub 2009 Nov 18. Review. PubMed PMID: 19922468.

30: Takeuchi K, Ito F. EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. FEBS J. 2010 Jan;277(2):316-26. Epub 2009 Nov 18. Review. PubMed PMID: 19922467.

31: Yano S. [Molecular-targeted therapy in the developing stage. 1) VEGFR-TKI and EGFR-TKI]. Nippon Naika Gakkai Zasshi. 2009 Aug 10;98(8):1887-93. Review. Japanese. PubMed PMID: 19894348.

32: Ray M, Salgia R, Vokes EE. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist. 2009 Nov;14(11):1116-30. Epub 2009 Nov 5. Review. PubMed PMID: 19892771.

33: Gridelli C, Maione P, Rossi A, Ferrara ML, Castaldo V, Palazzolo G, Mazzeo N. Treatment of advanced non-small-cell lung cancer in the elderly. Lung Cancer. 2009 Dec;66(3):282-6. Epub 2009 Oct 29. Review. PubMed PMID: 19879012.

34: Sanford M, Scott LJ. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Drugs. 2009 Nov 12;69(16):2303-28. doi: 10.2165/10489100-000000000-00000. Review. PubMed PMID: 19852530.

35: Ishikawa T, Nakagawa H. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. J Exp Ther Oncol. 2009;8(1):5-24. Review. PubMed PMID: 19827267.

36: Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs. 2009

Nov;20(10):851-5. Review. PubMed PMID: 19826350.

37: Tsimberidou AM, Braiteh F, Stewart DJ, Kurzrock R. Ultimate fate of oncology

drugs approved by the us food and drug administration without a randomized Trial. J Clin Oncol. 2009 Dec 20;27(36):6243-50. Epub 2009 Oct 13. Review. PubMed PMID:

19826112.

38: Bose P, Ozer H. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs. 2009 Nov;18(11):1735-51. Review. PubMed PMID: 19780706.

39: Tan EH, Chan A. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother. 2009 Oct;43(10):1658-66. Epub 2009 Sep 15. Review. PubMed PMID: 19755624.

40: Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009;48(7):964-70. Review. PubMed PMID: 19734999.

41: van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. Epub 2009 Sep 5. Review. PubMed PMID: 19733976.

42: An Y, Ongkeko WM. ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1529-42. Review. PubMed PMID: 19708828.

43: Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review

on pharmacology, metabolism and side effects. Curr Drug Metab. 2009 Jun;10(5):470-81. Review. PubMed PMID: 19689244.

44: Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene. 2009 Aug;28 Suppl 1:S32-7. Review. PubMed PMID: 19680294.

45: Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009 Aug;28 Suppl 1:S24-31. Review. PubMed PMID: 19680293; PubMed Central PMCID:

PMC2849651.

46: John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell lung

cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.

Oncogene. 2009 Aug;28 Suppl 1:S14-23. Review. PubMed PMID: 19680292.

47: Rukazenkov Y, Speake G, Marshall G, Anderton J, Davies BR, Wilkinson RW, Mark Hickinson D, Swaisland A. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? Anticancer Drugs. 2009 Nov;20(10):856-66. Review. PubMed PMID: 19657272.

48: Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009 Jul;10(4):281-9. Review. PubMed PMID: 19632948; PubMed Central PMCID: PMC2758558.

49: Mitsudomi T. [Small-molecule tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR)]. Gan To Kagaku Ryoho. 2009 Jul;36(7):1058-62. Review. Japanese. PubMed PMID: 19620791.

50: Loew S, Schmidt U, Unterberg A, Halatsch ME. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem. 2009 Jul;9(6):703-15. Review. PubMed PMID: 19601750.

51: Pallis AG, Serfass L, Dziadziusko R, van Meerbeeck JP, Fennell D, Lacombe D,

Welch J, Gridelli C. Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer. 2009 Sep;45(14):2473-87. Review. PubMed PMID: 19596191.

52: Johnston SR. Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer. 2009 Jun;9 Suppl 1:S28-36. Review. PubMed PMID: 19561004.

53: Pennell NA, Mekhail T. Investigational agents in the management of non-small

cell lung cancer. Curr Oncol Rep. 2009 Jul;11(4):275-84. Review. PubMed PMID: 19508832.

54: Caraglia M, Marra M, Tagliaferri P, Lamberts SW, Zappavigna S, Misso G, Cavagnini F, Facchini G, Abbruzzese A, Hofland LJ, Vitale G. Emerging strategies

to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets. 2009 Aug;9(5):690-704. Epub 2009 Aug 1. Review. PubMed PMID: 19508175.

55: Murakami Y. [Advances in genome analysis of solid tumors]. Nippon Rinsho. 2009 Jun;67(6):1115-9. Review. Japanese. PubMed PMID: 19507502.

56: Gridelli C, Maione P, Rossi A, Palazzolo G, Colantuoni G, Rossi E. Management of unfit older patients with advanced NSCLC. Cancer Treat Rev. 2009 Oct;35(6):517-21. Epub 2009 May 19. Review. PubMed PMID: 19457617.

57: Chang BW, Saif MW. Combining epidermal growth factor receptor inhibitors and

radiation therapy in pancreatic cancer: small step or giant leap? JOP. 2009 May 18;10(3):231-6. Review. PubMed PMID: 19454812.

58: Homs MY, Voest EE, Siersema PD. Emerging drugs for esophageal cancer. Expert

Opin Emerg Drugs. 2009 Jun;14(2):329-39. Review. PubMed PMID: 19453287.

59: Baron AT, Wilken JA, Haggstrom DE, Goodrich ST, Maihle NJ. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. IDrugs. 2009 May;12(5):302-8. Review. PubMed PMID: 19431095.

60: Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist. 2009 May;14(5):478-88. Epub 2009 May 1. Review. PubMed PMID: 19411318.

61: Saijo N, Takeuchi M, Kunitoh H. Reasons for response differences seen in the

V15-32, INTEREST and IPASS trials. Nat Rev Clin Oncol. 2009 May;6(5):287-94. Review. PubMed PMID: 19390555.

62: Cooper JB, Cohen EE. Mechanisms of resistance to EGFR inhibitors in head and

neck cancer. Head Neck. 2009 Aug;31(8):1086-94. Review. PubMed PMID: 19378324.

63: Reck M. Gefitinib in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther. 2009 Apr;9(4):401-12. Review. PubMed PMID: 19374595.

64: Pennell NA, Lynch TJ Jr. Combined inhibition of the VEGFR and EGFR signaling

pathways in the treatment of NSCLC. Oncologist. 2009 Apr;14(4):399-411. Epub 2009 Apr 8. Review. PubMed PMID: 19357226.

65: Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di

Maio M, De Maio E, Normanno N, Perrone F. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist. 2009 Apr;14(4):378-90. Epub 2009 Apr 6. Review. PubMed PMID: 19349511.

66: Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc

Am Thorac Soc. 2009 Apr 15;6(2):201-5. Review. PubMed PMID: 19349489.

67: Lin CC, Yang CH. Epidermal growth factor receptor tyrosine kinase inhibitors

in elderly or poor performance status patients with advanced non-small cell lung

cancer. Target Oncol. 2009 Jan;4(1):37-44. Epub 2009 Jan 20. Review. PubMed PMID: 19343300.

68: Gemma A. Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents. J Nippon Med Sch. 2009 Feb;76(1):4-8. Review. PubMed PMID: 19305103.

69: Dreyer C, Raymond E, Faivre S. [Targeted therapies and their indications in solid neoplasias]. Rev Med Interne. 2009 May;30(5):416-24. Epub 2009 Mar 18. Review. French. PubMed PMID: 19299048.

70: Johnson LN. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys. 2009 Feb;42(1):1-40. Epub 2009 Mar 19. Review. PubMed PMID: 19296866.

71: Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer. 2009 Jan;10(1):28-35. Review. PubMed PMID: 19289369.

72: Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 2009 Mar;9(2):237-49. Review. PubMed PMID: 19275762.

73: Sharma PS, Sharma R, Tyagi T. Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. Curr Pharm Des. 2009;15(7):758-76. Review. PubMed PMID: 19275641.

74: Mukherji D, Spicer J. Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opin Investig Drugs. 2009 Mar;18(3):293-301. Review. PubMed PMID: 19243280.

75: Popescu I. [Pre-neoplastic bronchial lesions: possibilities of diagnosis and

chemo-prevention]. Pneumologia. 2008 Oct-Dec;57(4):201-8. Review. Romanian. PubMed PMID: 19186682.

76: Tassinari D, Carloni F, Santelmo C, Tamburini E, Lazzari Agli L, Tombesi P, Sartori S. Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature. Rev Recent Clin Trials. 2009 Jan;4(1):27-33. Review. PubMed PMID: 19149760.

77: Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem. 2009 Jan;9(1):66-76. Review. PubMed PMID: 19149483.

78: Galetta D, Rossi A, Colucci G, Gebbia V. Third-line therapy for advanced non-small-cell lung cancer patients: a feasible therapeutic option? Oncology. 2009;77 Suppl 1:113-21. Epub 2010 Feb 2. Review. PubMed PMID: 20130439.

79: Rossi A, Galetta D, Gridelli C. Biological prognostic and predictive factors

in lung cancer. Oncology. 2009;77 Suppl 1:90-6. Epub 2010 Feb 2. Review. PubMed PMID: 20130436.

80: Barlesi F, Breen D. [Targeting HER pathway in head and neck and thoracic cancers]. Bull Cancer. 2009;96 Suppl 1:S35-43. Review. French. PubMed PMID: 19433372.

81: Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009

Jan 31;61(1):26-33. Epub 2008 Dec 3. Review. PubMed PMID: 19111841.

82: Hida T, Ogawa S, Park JC, Park JY, Shimizu J, Horio Y, Yoshida K. Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther. 2009 Jan;9(1):17-35. Review. PubMed PMID: 19105704.

83: Heist RS, Christiani D. EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics. 2009 Jan;10(1):59-68. Review. PubMed PMID: 19102716; PubMed Central PMCID: PMC2669783.

84: Jiang H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol. 2009 Mar;39(3):137-50. Epub 2008 Dec 16. Review. PubMed PMID: 19088154.

85: Aifa S, Rebai A. ErbB antagonists patenting: "playing chess with cancer". Recent Pat Biotechnol. 2008;2(3):181-7. Review. PubMed PMID: 19075865.

86: Harichand-Herdt S, Ramalingam SS. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor. Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):217-23. Review. PubMed PMID: 19038731.

87: Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor

for the treatment of solid tumors. Curr Opin Investig Drugs. 2008 Dec;9(12):1336-46. Review. PubMed PMID: 19037840.

88: Omuro AM. Exploring multi-targeting strategies for the treatment of gliomas.

Curr Opin Investig Drugs. 2008 Dec;9(12):1287-95. Review. PubMed PMID: 19037835.

89: Imianitov EN. [Molecular diagnosis in oncology]. Mol Biol (Mosk). 2008 Sep-Oct;42(5):772-85. Review. Russian. PubMed PMID: 18988527.

90: Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung

cancer therapy. Br J Cancer. 2008 Dec 2;99(11):1757-62. Epub 2008 Nov 4. Review.

PubMed PMID: 18985035; PubMed Central PMCID: PMC2600690.

91: Gupta R, Dastane AM, McKenna R Jr, Marchevsky AM. The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis. Hum Pathol. 2009 Mar;40(3):356-65. Epub 2008 Oct 30. Review. PubMed PMID: 18976796.

92: Sattler M, Abidoye O, Salgia R. EGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal. 2008 Sep 21;8:909-19. Review. PubMed PMID: 18836658.

93: Loeffler-Ragg J, Schwentner I, Sprinzl GM, Zwierzina H. EGFR inhibition as a

therapy for head and neck squamous cell carcinoma. Expert Opin Investig Drugs. 2008 Oct;17(10):1517-31. Review. PubMed PMID: 18808311.

94: Tamura K. [Targeted therapies for lung cancer]. Rinsho Ketsueki. 2008 Aug;49(8):616-21. Review. Japanese. PubMed PMID: 18800610.

95: Rapidis AD, Vermorken JB, Bourhis J. Targeted therapies in head and neck cancer: past, present and future. Rev Recent Clin Trials. 2008 Sep;3(3):156-66. Review. PubMed PMID: 18782074.

96: Yamamoto H, Toyooka S, Mitsudomi T. Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer. 2009 Mar;63(3):315-21. Epub 2008 Aug 29. Review. PubMed PMID: 18760859.

97: Charpidou A, Blatza D, Anagnostou V, Syrigos KN. Review. EGFR mutations in non-small cell lung cancer--clinical implications. In Vivo. 2008 Jul-Aug;22(4):529-36. Review. Erratum in: In Vivo. 2008 Nov-Dec;22(6):886. Anagnostou, Elsa [corrected to Anagnostou, Valsamo]. PubMed PMID: 18712184.

98: Magné N, Chargari C, Castadot P, Ghalibafian M, Soria JC, Haie-Meder C, Bourhis J, Deutsch E. The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials. Eur J Cancer. 2008 Oct;44(15):2133-43. Epub 2008 Aug 7. Review. PubMed PMID: 18692389.

99: Brockstein B, Lacouture M, Agulnik M. The role of inhibitors of the epidermal growth factor in management of head and neck cancer. J Natl Compr Canc Netw. 2008 Aug;6(7):696-706. Review. PubMed PMID: 18691458.

100: Zhukov NV, Tjulandin SA. Targeted therapy in the treatment of solid tumors:

practice contradicts theory. Biochemistry (Mosc). 2008 May;73(5):605-18. Review.

PubMed PMID: 18605984.

101: Wallerand H, Robert G, Bernhard JC, Ravaud A, Ferrière JM. [Targeted therapy for locally advanced and/or metastatic bladder cancer]. Prog Urol. 2008 Jul;18(7):407-17. Epub 2008 Jun 26. Review. French. PubMed PMID: 18602599.

102: Fukai M, Mori M, Namba Y, Fushitani K, Nakazawa Y, Yano Y, Niinaka M, Kimura H, Naka N, Okada T, Nakagawa M, Yokota S. [Case of bilateral pneumothorax observed during the administration of gefitinib for lung adenocarcinoma with multiple pulmonary metastases]. Nihon Kokyuki Gakkai Zasshi. 2008 Jun;46(6):483-7. Review. Japanese. PubMed PMID: 18592995.

103: Reck M, Crinò L. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer. 2009 Jan;63(1):1-9. Epub 2008 Jun 25. Review. PubMed PMID: 18579254.

104: Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S146-9. Review. PubMed PMID: 18520300.

105: Lind JS, Herder GJ, Smit EF. [New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis]. Ned Tijdschr Geneeskd. 2008 Apr 19;152(16):928-32. Review. Dutch. PubMed PMID: 18561788.

106: Dunsford J. Nursing management of epidermal growth factor receptor inhibitor-induced toxicities. Clin J Oncol Nurs. 2008 Jun;12(3):405-7. Review. PubMed PMID: 18515238.

107: Jänne PA. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer. 2008 Jun;60 Suppl 2:S3-9. Review. PubMed PMID: 18513582.

108: Yang CH. EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East

Asia: present and future. Lung Cancer. 2008 Jun;60 Suppl 2:S23-30. Review. PubMed PMID: 18513581.

109: Riely GJ. The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. Lung Cancer. 2008 Jun;60 Suppl 2:S19-22. Review. PubMed PMID: 18513580.

110: Gridelli C, Rossi A, Maione P, Ferrara C, Del Gaizo F, Guerriero C, Nicolella D, Palazzolo G, Falanga M, Colantuoni G. New insights in drug development for the non-small cell lung cancer therapy. Front Biosci. 2008 May 1;13:5108-19. Review. PubMed PMID: 18508573.

111: Milano G, Spano JP, Leyland-Jones B. EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. Br J Cancer.

2008 Jul 8;99(1):1-5. Epub 2008 May 27. Review. PubMed PMID: 18506149; PubMed Central PMCID: PMC2453033.

112: Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am. 2008 Jun;37(2):511-24, xi. Review. PubMed PMID: 18502340.

113: Saijo N. Advances in the treatment of non-small cell lung cancer. Cancer Treat Rev. 2008 Oct;34(6):521-6. Epub 2008 May 22. Review. PubMed PMID: 18501519.

114: Wissner A, Mansour TS. The development of HKI-272 and related compounds for

the treatment of cancer. Arch Pharm (Weinheim). 2008 Aug;341(8):465-77. Review. PubMed PMID: 18493974.

115: Akita H, Kinoshita I. [Non-small-cell lung cancer]. Gan To Kagaku Ryoho. 2008 May;35(5):720-4. Review. Japanese. PubMed PMID: 18487906.

116: van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat. 2008 Jun;11(3):77-98. Epub 2008 May 19. Review. PubMed PMID: 18486526.

117: Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008 May 15;14(10):2895-9. Review. PubMed PMID: 18483355.

118: Pande AU, Iyer RV, Rani A, Maddipatla S, Yang GY, Nwogu CE, Black JD, Levea

CM, Javle MM. Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology. 2007;73(5-6):281-9. Epub 2008 May 14. Review. PubMed PMID: 18477853.

119: Salgaller ML, Liau LM. Current status of clinical trials for glioblastoma. Rev Recent Clin Trials. 2006 Sep;1(3):265-81. Review. PubMed PMID: 18473979.

120: Carcereny E, Maurel J. Monoclonal antibodies against epidermal growth factor receptor in advanced colorectal carcinoma: clinical efficacy and markers of sensitivity. Rev Recent Clin Trials. 2006 May;1(2):113-8. Review. PubMed PMID: 18473962.

121: Okamoto I. Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan. Int J Clin Oncol. 2008 Apr;13(2):112-6. Epub 2008 May 8. Review. PubMed PMID: 18463953.

122: Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc.

2008 May;83(5):584-94. Review. PubMed PMID: 18452692; PubMed Central PMCID: PMC2718421.

123: Hamakawa H, Nakashiro K, Sumida T, Shintani S, Myers JN, Takes RP, Rinaldo A, Ferlito A. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck. 2008 Jun;30(6):800-9. Review. PubMed PMID: 18429007.

124: Hamburger AW. The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies. J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):225-33. Epub 2008 Apr 19. Review. PubMed PMID: 18425425.

125: Metro G, Finocchiaro G, Toschi L, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L, Cappuzzo F. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).

Rev Recent Clin Trials. 2006 Jan;1(1):1-13. Review. PubMed PMID: 18393776.

126: Prenen H, Kimpe M, Nuyts S. Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets. Curr Opin Oncol. 2008 May;20(3):270-4. Review. PubMed PMID: 18391625.

127: De Grève J, Decoster L, Van Meerbeek J, Vermeij J, Teugels E, Schallier D. [Targeted therapies in the treatment of non-small cell lung cancer]. Bull Cancer. 2008 Mar;95(3):358-64. Review. French. PubMed PMID: 18390417.

128: Okano Y, Nishio M. [Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis]. Clin Calcium. 2008 Apr;18(4):527-33. Review. Japanese. PubMed PMID: 18379035.

129: Fojo T. Commentary: Novel therapies for cancer: why dirty might be better. Oncologist. 2008 Mar;13(3):277-83. Review. PubMed PMID: 18378537.

130: Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of

the epidermal growth factor receptor in human cancer. J Clin Oncol. 2008 Apr 1;26(10):1742-51. Review. PubMed PMID: 18375904.

131: Vattemi E, Graiff C, Sava T, Pedersini R, Caldara A, Mandarà M. Systemic therapies for recurrent and/or metastatic salivary gland cancers. Expert Rev Anticancer Ther. 2008 Mar;8(3):393-402. Review. PubMed PMID: 18366287.

132: Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol. 2008 Apr;58(4):545-70. Review. PubMed PMID: 18342708.

133: Fukui T, Mitsudomi T. Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. Gen Thorac Cardiovasc Surg. 2008 Mar;56(3):97-103. Epub 2008 Mar 14. Review. PubMed PMID: 18340507.

134: Fujii T, Yokoyama G, Takahashi H, Toh U, Kage M, Ono M, Shirouzu K, Kuwano M. Preclinical and clinical studies of novel breast cancer drugs targeting molecules involved in protein kinase C signaling, the putative metastasis-suppressor gene Cap43 and the Y-box binding protein-1. Curr Med Chem.

2008;15(6):528-37. Review. PubMed PMID: 18336267.

135: Bunn PA Jr, Thatcher N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist. 2008;13 Suppl 1:37-46. Review. PubMed PMID: 18263773.

136: Chang AY. The role of gefitinib in the management of Asian patients with non-small cell lung cancer. Expert Opin Investig Drugs. 2008 Mar;17(3):401-11. Review. Erratum in: Expert Opin Investig Drugs. 2008 May;17(5):825. PubMed PMID:

18321238.

137: Fong T, Morgensztern D, Govindan R. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol. 2008 Mar;3(3):303-10. Review. PubMed PMID: 18317074.

138: Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008 Mar;83(3):355-67. Review. PubMed PMID: 18316005.

139: Wheatley-Price P, Shepherd FA. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr Opin Oncol. 2008 Mar;20(2):162-75. Review. PubMed PMID: 18300766.

140: Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem. 2008;15(5):422-32. Review. PubMed PMID: 18288997.

141: Pérol M, Arpin D. [Tyrosine kinase inhibitors in the management of non-small cell lung cancer]. Rev Mal Respir. 2007 Oct;24(8 Pt 2):6S188-97. Review. French.

PubMed PMID: 18235413.

142: Brandes AA, Franceschi E, Tosoni A, Hegi ME, Stupp R. Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res. 2008 Feb 15;14(4):957-60. Review. PubMed PMID: 18281526.

143: Voelzke WR, Petty WJ, Lesser GJ. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr Treat Options Oncol. 2008 Feb;9(1):23-31. Epub 2008 Feb 5. Review. PubMed PMID: 18247132.

144: Miller VA. EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. Semin Oncol Nurs. 2008 Feb;24(1):27-33. Review. PubMed PMID: 18222149.

145: Becker JC, Ugurel S, Schrama D. Strategies to optimize the use of targeted agents for tumor therapy. J Dtsch Dermatol Ges. 2008 Apr;6(4):281-5. Epub 2008 Jan 17. Review. English, German. PubMed PMID: 18205839.

146: Kano Y. [Adverse drug reactions induced by molecular target therapy]. Arerugi. 2007 Dec;56(12):1485-91. Review. Japanese. PubMed PMID: 18195551.

147: Pirker R, Minar W, Filipits M. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer. Clin Lung Cancer. 2008;9 Suppl 3:S109-15. Review. PubMed PMID: 19419924.

148: Ploner F. [NSCLC: update on second line therapy following ASCO 2007]. Wien Med Wochenschr. 2007;157(21-22):540-4. Review. German. PubMed PMID: 18157591.

149: Kubo K. [Drug-induced pulmonary edema]. Nippon Rinsho. 2007 Oct 28;65 Suppl

8:420-5. Review. Japanese. PubMed PMID: 18072347.

150: Palayekar MJ, Herzog TJ. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int J Gynecol Cancer. 2008 Sep-Oct;18(5):879-90. Epub 2007 Dec 5. Review. PubMed PMID: 18053062.

151: Ahmed SM, Cohen EE. Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the

emergence of small molecule epidermal growth factor receptor kinase inhibitors. Curr Cancer Drug Targets. 2007 Nov;7(7):666-73. Review. PubMed PMID: 18045071.

152: Srivastava SK, Jha A, Agarwal SK, Mukherjee R, Burman AC. Synthesis and structure-activity relationships of potent antitumor active quinoline and naphthyridine derivatives. Anticancer Agents Med Chem. 2007 Nov;7(6):685-709. Review. PubMed PMID: 18045063.

153: Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol. 2008 Jan;20(1):104-11. Review. PubMed PMID: 18043264.

154: Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol. 2008 Jan;20(1):19-24. Review. PubMed PMID: 18043252.

155: Grávalos C, Cassinello J, Fernández-Rañada I, Holgado E. Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer. Clin Colorectal Cancer. 2007 Nov;6(10):691-9. Review. PubMed PMID: 18039422.

156: Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar)

in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol. 2008 Apr;61(4):535-48. Epub 2007 Nov 17. Review. PubMed PMID: 18026728.

157: Kim TY, Han SW, Bang YJ. Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. Expert Rev Mol Diagn. 2007 Nov;7(6):821-36. Review. PubMed PMID: 18020911.

158: Ng K, Zhu AX. Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hematol. 2008 Jan;65(1):8-20. Epub 2007 Nov 19. Review. PubMed PMID: 18006328.

159: Ponz-Sarvisé M, Rodríguez J, Viudez A, Chopitea A, Calvo A, García-Foncillas J, Gil-Bazo I. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new? World J Gastroenterol. 2007 Nov 28;13(44):5877-87. Review. PubMed PMID: 17990353.

160: Yong WP, Innocenti F. Translation of pharmacogenetic knowledge into cancer therapeutics. Clin Adv Hematol Oncol. 2007 Sep;5(9):698-706. Review. PubMed PMID: 17982411.

161: Italiano A, Besse B, Planchard D, Soria JC. [Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]. Bull Cancer. 2007;94(7 Suppl):F177-88. Review. French. PubMed PMID: 17964994.

162: Fumoleau P, Campone M, Coudert B, Mayer F, Favier L, Ferrant E. [Targeting ErbB receptors in breast cancer]. Bull Cancer. 2007;94(7 Suppl):F147-70. Review.

French. PubMed PMID: 17964992.

163: Thatcher N. The place of targeted therapy in the patient management of non-small cell lung cancer. Lung Cancer. 2007 Aug;57 Suppl 2:S18-23. Review. PubMed PMID: 17686441.

164: Willett CG, Duda DG, Czito BG, Bendell JC, Clark JW, Jain RK. Targeted therapy in rectal cancer. Oncology (Williston Park). 2007 Aug;21(9):1055-65; discussion 1065, 1070, 1075 passim. Review. PubMed PMID: 17910311; PubMed Central PMCID: PMC2686129.

165: Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007 Dec;98(12):1817-24. Epub 2007 Sep 20. Review. PubMed PMID: 17888036.

166: Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs. 2007;67(14):2045-75. Review. PubMed PMID: 17883287.

167: Nielsen DL, Andersson M. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors]. Ugeskr Laeger. 2007 Sep 10;169(37):3085-7. Review. Danish. PubMed PMID: 17877954.

168: Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol. 2007 Sep 10;25(26):4057-65. Review.

PubMed PMID: 17827454.

169: Lacouture ME, Melosky BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett. 2007 Jul-Aug;12(6):1-5. Review. PubMed PMID: 17762902.

170: Ding J, Feng Y, Wang HY. From cell signaling to cancer therapy. Acta Pharmacol Sin. 2007 Sep;28(9):1494-8. Review. PubMed PMID: 17723182.

171: Kurtin SE. Targeting the epidermal growth factor receptor in colorectal carcinoma. Cancer Nurs. 2007 Jul-Aug;30(4 Suppl 1):S1-9. Review. PubMed PMID: 17666985.

172: Fukui T, Mitsudomi T. [Gefitinib and epidermal growth factor receptor gene mutation]. Gan To Kagaku Ryoho. 2007 Aug;34(8):1168-72. Review. Japanese. PubMed

PMID: 17687196.

173: Tsukuda M. [Head and neck: molecular-targeted therapy]. Gan To Kagaku Ryoho. 2007 Jul;34(7):1034-9. Review. Japanese. PubMed PMID: 17682304.

174: Koike A, Ohta T. [Predictive markers in breast cancer treatment--focusing on a recent topic "basal-like breast cancer"]. Nippon Rinsho. 2007 Jun 28;65 Suppl 6:285-90. Review. Japanese. PubMed PMID: 17682168.

175: Cadranel J, Wislez M, Gounant V, Lavolé A, Antoine M, Milleron B. [Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?]. Rev Pneumol Clin. 2007 Jun;63(3):147-54. Review. French. PubMed PMID: 17675938.

176: Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist. 2007 Jul;12(7):840-9. Review. PubMed PMID: 17673615.

177: Hanrahan EO, Heymach JV. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4617-22. Review. PubMed PMID: 17671152.

178: Wong KK. HKI-272 in non small cell lung cancer. Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4593-6. Review. PubMed PMID: 17671147.

179: Lustberg MB, Edelman MJ. Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol. 2007 Feb;8(1):38-46. Review. PubMed PMID: 17634834.

180: Hann CL, Brahmer JR. "Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?". Curr Treat Options Oncol. 2007 Feb;8(1):28-37. Review. PubMed PMID: 17634830.

181: Johnston SR, Martin LA, Leary A, Head J, Dowsett M. Clinical strategies for

rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):180-6. Epub 2007 May 24. Review. PubMed PMID: 17624764.

182: Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther. 2007 Jul;6(7):1909-19. Review. PubMed PMID: 17620423.

183: Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control. 2007 Jul;14(3):295-304. Review. PubMed PMID: 17615536.

184: Ishikawa N. [Major drug-induced lung diseases: adverse effects of newly developed molecular targeted drugs]. Nippon Naika Gakkai Zasshi. 2007 Jun 10;96(6):1129-36. Review. Japanese. PubMed PMID: 17607988.

185: Kubota K. [What is drug-epidemiology?]. Nippon Naika Gakkai Zasshi. 2007 Jun 10;96(6):1083-90. Review. Japanese. PubMed PMID: 17607981.

186: Grosicki S, Grosicka A, Hołowiecki J. [Clinical importance of angiogenesis and angiogenic factors in oncohematology]. Wiad Lek. 2007;60(1-2):39-46. Review.

Polish. PubMed PMID: 17607967.

187: O'Donovan N, Crown J. EGFR and HER-2 antagonists in breast cancer. Anticancer Res. 2007 May-Jun;27(3A):1285-94. Review. PubMed PMID: 17593621.

188: Juergens R, Brahmer J. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how? Curr Oncol Rep. 2007 Jul;9(4):255-64. Review. PubMed PMID: 17588349.

189: Tschoep K, Kohlmann A, Schlemmer M, Haferlach T, Issels RD. Gene expression

profiling in sarcomas. Crit Rev Oncol Hematol. 2007 Aug;63(2):111-24. Epub 2007 Jun 6. Review. PubMed PMID: 17555981.

190: Bencardino K, Manzoni M, Delfanti S, Riccardi A, Danova M, Corazza GR. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of

non-small-cell lung cancer: results and open issues. Intern Emerg Med. 2007 Mar;2(1):3-12. Epub 2007 Mar 31. Review. PubMed PMID: 17551677; PubMed Central PMCID: PMC2780603.

191: Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int J Mol

Med. 2007 Jul;20(1):3-10. Review. PubMed PMID: 17549382.

192: Dancey JE. Epidermal growth factor receptor inhibitors in non-small cell lung cancer. Drugs. 2007;67(8):1125-38. Review. PubMed PMID: 17521215.

193: Tortora G, Gelardi T, Ciardiello F, Bianco R. The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S47-52. Review. PubMed PMID: 17520581.

194: Dei Tos AP. The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor. Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S3-9. Review. PubMed PMID: 17520579.

195: Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G. Pharmacology of epidermal growth factor inhibitors. Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S24-39. Review. PubMed PMID: 17520578.

196: Cappuzzo F, Toschi L, Finocchiaro G, Ligorio C, Santoro A. Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S10-23. Review. PubMed PMID: 17520577.

197: Yatabe Y, Mitsudomi T. Epidermal growth factor receptor mutations in lung cancers. Pathol Int. 2007 May;57(5):233-44. Review. PubMed PMID: 17493170.

198: Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R

Coll Radiol). 2007 Aug;19(6):397-417. Epub 2007 May 2. Review. PubMed PMID: 17478086.

199: Zalcman G, Richard N, Bergot E. [New biological treatments for lung cancer]. Rev Pneumol Clin. 2007 Feb;63(1):20-8. Review. French. PubMed PMID: 17457280.

200: Uramoto H, Sugio K, Yasumoto K. [Prediction of effectiveness of EGFR tyrosine kinase inhibitors for the patients with by EGFR mutations]. Gan To Kagaku Ryoho. 2007 Apr;34(4):538-43. Review. Japanese. PubMed PMID: 17431338.

201: Kris MG, Giaccone G, Davies A, Fukuoka M, Garfield DH, Jassem J, Quoix EA, Sandler AB, Scagliotti GV, Van Meerbeeck JP, West H. Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. J Thorac Oncol. 2006 Nov;1(9 Suppl):S32-6. PubMed PMID: 17409999.

202: Noble J, Ellis PM, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol. 2006 Nov;1(9):1042-58.

Review. PubMed PMID: 17409993.

203: Kurata T, Matsuo K, Takada M, Kawahara M, Tsuji M, Matsubara Y, Otani N, Matsuyama S, Muraishi K, Fujita T, Ishikawa M, Koyano K, Okamoto I, Satoh T, Tamura K, Nakagawa K, Fukuoka M. Is the importance of achieving stable disease different between epidermal growth factor receptor tyrosine kinase inhibitors and cytotoxic agents in the second-line setting for advanced non-small cell lung cancer? J Thorac Oncol. 2006 Sep;1(7):684-91. Review. PubMed PMID: 17409937.

204: Feld R, Sridhar SS, Shepherd FA, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J Thorac Oncol. 2006 May;1(4):367-76. Review. PubMed PMID: 17409886.

205: Sequist LV. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist. 2007 Mar;12(3):325-30. Review. PubMed PMID: 17405897.

206: Gandara DR, Davies AM, Gautschi O, Mack PC, Lau DH, Lara PN Jr, Hirsch FR. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clin Lung Cancer. 2007 Feb;8 Suppl 2:S61-7. Review. PubMed PMID: 17382026.

207: Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett. 2007 Sep 8;254(2):165-77. Epub 2007 Mar 23. Review. PubMed PMID: 17367921; PubMed Central PMCID: PMC1986742.

208: Irmer D, Funk JO, Blaukat A. EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy. Oncogene. 2007 Aug 23;26(39):5693-701. Epub 2007 Mar 12. Review. PubMed PMID: 17353898.

209: Ono A, Yamamoto N. [Lung cancer]. Gan To Kagaku Ryoho. 2007 Mar;34(3):367-73. Review. Japanese. PubMed PMID: 17353626.

210: Milano A, Longo F, Basile M, Iaffaioli RV, Caponigro F. Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy.

Oral Oncol. 2007 Sep;43(8):729-34. Epub 2007 Mar 9. Review. PubMed PMID: 17350323.

211: Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions,

epigenetic changes and microRNAs. Drug Resist Updat. 2007 Feb-Apr;10(1-2):59-67.

Epub 2007 Mar 9. Review. PubMed PMID: 17350322.

212: Verguts J, Amant F, Moerman P, Vergote I. HPV induced ovarian squamous cell

carcinoma: case report and review of the literature. Arch Gynecol Obstet. 2007 Sep;276(3):285-9. Epub 2007 Feb 28. Review. PubMed PMID: 17333225.

213: Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer. 2007 Mar 26;96(6):857-63. Epub 2007 Feb 27. Review. PubMed PMID: 17325698; PubMed Central PMCID: PMC2360106.

214: Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol. 2007 Apr;62(1):53-61. Epub 2007 Feb 26. Review. PubMed PMID: 17324578.

215: Duster T. Medicalisation of race. Lancet. 2007 Feb 24;369(9562):702-4. Review. PubMed PMID: 17321318.

216: Brown MP, Buckley MF, Rudzki Z, Olver IN. Why we will need to learn new skills to control cancer. Intern Med J. 2007 Mar;37(3):201-4. Review. PubMed PMID: 17316345.

217: Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, Kavanagh JJ. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007 Jul-Aug;17(4):739-63. Epub 2007 Feb 16. Review. PubMed PMID: 17309673.

218: Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007 Feb 10;25(5):587-95. Review. PubMed PMID: 17290067.

219: Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007 Feb 10;25(5):561-70. Review. PubMed PMID: 17290066.

220: Blackhall FH, Shepherd FA. Small cell lung cancer and targeted therapies. Curr Opin Oncol. 2007 Mar;19(2):103-8. Review. PubMed PMID: 17272981.

221: Iwanaga K, Tohda Y. [Drug-induced lung injury]. Arerugi. 2007 Jan;56(1):37-40. Review. Japanese. PubMed PMID: 17272956.

222: Scagliotti GV, Selvaggi G. The place of targeted therapies in the management of non-small cell bronchial carcinoma. Target therapies in lung cancer management. Rev Mal Respir. 2006 Nov;23(5 Pt 3):16S137-16S147. Review. PubMed PMID: 17268351.

223: Hutcheson IR, Knowlden JM, Jones HE, Burmi RS, McClelland RA, Barrow D, Gee

JM, Nicholson RI. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S89-97. Review. PubMed PMID: 17259562.

224: Gee JM, Shaw VE, Hiscox SE, McClelland RA, Rushmere NK, Nicholson RI. Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S77-88.

Review. PubMed PMID: 17259561.

225: Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI. Growth

factor receptor interplay and resistance in cancer. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S45-51. Review. PubMed PMID: 17259558.

226: Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an

orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs.

2007 Feb;16(2):239-49. Review. PubMed PMID: 17243944.

227: Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer. 2006 Dec;8 Suppl 1:S7-14. Review. PubMed PMID: 17239291.

228: Chou LS, Garey J, Oishi K, Kim E. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. Clin Lung Cancer. 2006 Dec;8 Suppl 1:S15-22. Review. PubMed PMID: 17239286.

229: Grenier J, Soria JC. [Inhibitors of the EGFR pathway in non small cell lung

cancer: what's new in 2007?]. Bull Cancer. 2007 Jan 1;94(1):53-61. Review. French. PubMed PMID: 17237005.

230: Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007 Jun;18(6):977-84. Epub 2007 Jan 17. Review. PubMed PMID: 17229773.

231: Reuter CW, Morgan MA, Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer. 2007 Feb 12;96(3):408-16. Epub 2007 Jan 16. Review. PubMed PMID: 17224925; PubMed Central

PMCID: PMC2360023.

232: Gao XP, Liu F. New agents in development for breast cancer. Curr Opin Obstet Gynecol. 2007 Feb;19(1):68-74. Review. PubMed PMID: 17218855.

233: Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin

Cancer Res. 2006 Dec 15;12(24):7242-51. Review. PubMed PMID: 17189395.

234: Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006 Dec 15;12(24):7232-41. Review. PubMed PMID: 17189394.

235: Rosell R, Taron M, Reguart N, Isla D, Moran T. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin Cancer Res. 2006 Dec 15;12(24):7222-31. Review. PubMed PMID: 17189393.

236: Sioud M, Leirdal M. Druggable signaling proteins. Methods Mol Biol. 2007;361:1-24. Review. PubMed PMID: 17172705.

237: Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H, Gingerich J, Skliris GP, Murphy LC, Los M. Targeting the EGFR pathway for cancer

therapy. Curr Med Chem. 2006;13(29):3483-92. Review. PubMed PMID: 17168718.

238: Zhang X, Chang A. Somatic mutations of the epidermal growth factor receptor

and non-small-cell lung cancer. J Med Genet. 2007 Mar;44(3):166-72. Epub 2006 Dec 8. Review. PubMed PMID: 17158592; PubMed Central PMCID: PMC2598028.

239: Pujol JL. [Is it possible to treat bronchial carcinoma without chemotherapy?]. Rev Mal Respir. 2006 Sep;23(4 Pt 2):10S23-10S26. Review. French.

PubMed PMID: 17127957.

240: Sotto-Mayor R. [Lung cancer in women: a different entity?]. Rev Port Pneumol. 2006 Sep-Oct;12(5):545-61. Review. Portuguese. PubMed PMID: 17117325.

241: Shchemelinin I, Sefc L, Necas E. Protein kinase inhibitors. Folia Biol (Praha). 2006;52(4):137-48. Review. PubMed PMID: 17116285.

242: Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol. 2007 Feb;14(2):942-53. Epub 2006 Nov 14. Review. PubMed PMID: 17103252.

243: Arslan MA, Kutuk O, Basaga H. Protein kinases as drug targets in cancer. Curr Cancer Drug Targets. 2006 Nov;6(7):623-34. Review. PubMed PMID: 17100568.

244: Pao W. Defining clinically relevant molecular subsets of lung cancer. Cancer Chemother Pharmacol. 2006 Nov;58 Suppl 1:s11-5. Review. PubMed PMID: 17093937.

245: Fartoux L, Desbois-Mouthon C, Poupon R, Rosmorduc O. [Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma]. Gastroenterol Clin Biol. 2006 Oct;30(10):1133-5. Review. French. PubMed PMID: 17075466.

246: Kato T, Nishio K. Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk. Respirology. 2006 Nov;11(6):693-8. Review. PubMed PMID: 17052296.

247: Ahmed SM, Salgia R. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology. 2006 Nov;11(6):687-92. Review. PubMed PMID: 17052295.

248: Azim HA Jr, Ganti AK. Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand? Cancer Treat Rev. 2006 Dec;32(8):630-6. Epub 2006 Oct 10. Review. PubMed PMID: 17034953.

249: Giannelli G, Antonaci S. Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J Clin Gastroenterol. 2006 Oct;40(9):842-6. Review. PubMed PMID: 17016142.

250: Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC.

Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006 Oct;55(4):657-70. Review. PubMed PMID: 17010747.

251: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):451-95. Review. PubMed PMID: 17003851.

252: Zucali PA, Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer. 2006 Nov;42(16):2706-14. Epub 2006 Sep 20. Review. PubMed PMID: 16989994.

253: Guhl G, González-de Arriba A, Daudén E. [Epidermal growth factor receptor inhibitors side effects]. Actas Dermosifiliogr. 2006 Jun;97(5):296-310. Review. Spanish. PubMed PMID: 16956561.

254: Chan SK, Hill ME, Gullick WJ. The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):3-11. Review. PubMed PMID: 16947082.

255: Morse L. Clinical breakthroughs in EGFR inhibition: applying the science to

your clinical practice. ONS News. 2006;21(8 Suppl):59-60. Review. PubMed PMID: 16925155.

256: Rubin BP, Duensing A. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab Invest. 2006 Oct;86(10):981-6. Epub 2006 Aug 21. Review. PubMed PMID: 16924245.

257: Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer. 2006 Sep 15;107(6):1207-18. Review. PubMed PMID: 16909423.

258: Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006 Aug;33(4):369-85. Review. PubMed PMID: 16890793.

259: Itoh Y, Sendo T, Oishi R. [Drug-induced lung diseases]. Nippon Yakurigaku Zasshi. 2006 Jun;127(6):425-32. Review. Japanese. PubMed PMID: 16880691.

260: Amler LC, Goddard AD, Hillan KJ. Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors. Cold Spring Harb Symp Quant Biol. 2005;70:483-8. Review. PubMed PMID: 16869787.

261: Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol. 2005;70:419-26. Review. PubMed PMID: 16869779.

262: Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4441s-4445s. Review. PubMed PMID: 16857825.

263: Dimitroulakos J, Lorimer IA, Goss G. Strategies to enhance epidermal growth

factor inhibition: targeting the mevalonate pathway. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4426s-4431s. Review. PubMed PMID: 16857822.

264: Jänne PA, Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4416s-4420s. Review. PubMed PMID: 16857820.

265: Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4403s-4408s. Review. PubMed PMID: 16857818.

266: Thomas RK, Weir B, Meyerson M. Genomic approaches to lung cancer. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4384s-4391s. Review. PubMed PMID: 16857815.

267: Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol. 2006 Jun;11(3):190-8. Review. PubMed PMID: 16850125.

268: Yamanaka T, Okamoto T, Ichinose Y, Oda S, Maehara Y. Methodological aspects

of current problems in target-based anticancer drug development. Int J Clin Oncol. 2006 Jun;11(3):167-75. Review. PubMed PMID: 16850122.

269: Chon HS, Hu W, Kavanagh JJ. Targeted therapies in gynecologic cancers. Curr

Cancer Drug Targets. 2006 Jun;6(4):333-63. Review. PubMed PMID: 16848724.

270: Auberger J, Loeffler-Ragg J, Wurzer W, Hilbe W. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. Curr Cancer Drug Targets. 2006 Jun;6(4):271-94. Review. PubMed PMID: 16848720.

271: Kudo S. [Drug induced lung injuries in Japanese population]. Nippon Naika Gakkai Zasshi. 2006 Jun 10;95(6):1058-62. Review. Japanese. PubMed PMID: 16846055.

272: Takahashi H, Shiratori M. [Diffuse lung diseases and biological markers in serum]. Nippon Naika Gakkai Zasshi. 2006 Jun 10;95(6):986-92. Review. Japanese. PubMed PMID: 16846044.

273: Kudoh S, Yoshimura A. [Current status and problems of anticancer drug-induced lung injuries]. Gan To Kagaku Ryoho. 2006 Jul;33(7):881-6. Review. Japanese. PubMed PMID: 16835472.

274: Pedersen MW, Poulsen HS. [Mutations in the epidermal growth factor receptor: structure and biological function in human tumors]. Ugeskr Laeger. 2006 Jun 12;168(24):2354-61. Review. Danish. PubMed PMID: 16822420.

275: Freeman BB 3rd, Daw NC, Geyer JR, Furman WL, Stewart CF. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest. 2006 Apr-May;24(3):310-7. Review. PubMed PMID: 16809160.

276: De Marinis F, De Santis S, De Petris L. Second-line chemotherapy for non-small cell lung cancer. Ann Oncol. 2006 May;17 Suppl 5:v68-71. Review. PubMed PMID: 16807467.

277: Eng C, Shalan N. Biological agents versus chemotherapy in the treatment of colorectal cancer. Expert Opin Pharmacother. 2006 Jul;7(10):1251-71. Review. PubMed PMID: 16805714.

278: Bremer E, van Dam G, Kroesen BJ, de Leij L, Helfrich W. Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med.

2006 Aug;12(8):382-93. Epub 2006 Jun 23. Review. PubMed PMID: 16798087.

279: Bogeschdorfer F, Gronau S, Riechelmann H. [New substances in the therapy of

head and neck cancer]. Laryngorhinootologie. 2006 Jul;85(7):520-9; quiz 530-1. Review. German. PubMed PMID: 16791768.

280: Sandler AB. Advanced non-small-cell lung cancer: new data, therapy choices,

and challenging decisions. Oncology (Williston Park). 2006 May;20(6):626-8. Review. PubMed PMID: 16773846.

281: von Eyben FE. Epidermal growth factor receptor inhibition and non-small cell lung cancer. Crit Rev Clin Lab Sci. 2006;43(4):291-323. Review. PubMed PMID: 16769595.

282: Rosell R, Cecere F, Santarpia M, Reguart N, Taron M. Predicting the outcome

of chemotherapy for lung cancer. Curr Opin Pharmacol. 2006 Aug;6(4):323-31. Epub

2006 Jun 12. Review. Erratum in: Curr Opin Pharmacol. 2007 Feb;7(1):119. PubMed PMID: 16765644.

283: Sakurada A, Shepherd FA, Tsao MS. Epidermal growth factor receptor tyrosine

kinase inhibitors in lung cancer: impact of primary or secondary mutations. Clin

Lung Cancer. 2006 May;7 Suppl 4:S138-44. Review. PubMed PMID: 16764754.

284: Ho C, Davies AM, Lara PN Jr, Gandara DR. Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. Clin Lung

Cancer. 2006 May;7 Suppl 4:S118-25. Review. PubMed PMID: 16764752.

285: Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy

in patients with recurrent and/or metastatic squamous cell carcinoma of the head

and neck. J Clin Oncol. 2006 Jun 10;24(17):2659-65. Review. PubMed PMID: 16763280.

286: Levitzki A, Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem. 2006;75:93-109. Review. PubMed PMID: 16756486.

287: Stukov AN, Gershanovich ML, Filov VA, Imianitov EN. [Problems in the current target therapy of malignancies]. Vopr Onkol. 2005;51(5):607-11. Review. Russian.

PubMed PMID: 16756022.

288: Blackhall F, Ranson M, Thatcher N. Where next for gefitinib in patients with lung cancer? Lancet Oncol. 2006 Jun;7(6):499-507. Review. Erratum in: Lancet Oncol. 2007 Aug;8(8):670. PubMed PMID: 16750500.

289: Sandler AB. Nondermatologic adverse events associated with anti-EGFR therapy. Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):35-40. Review. PubMed

PMID: 16736981.

290: Vokes EE, Chu E. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25. Review. PubMed PMID: 16736979.

291: Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):5-13.

Review. PubMed PMID: 16736978.

292: Martin P, Kelly CM, Carney D. Epidermal growth factor receptor-targeted agents for lung cancer. Cancer Control. 2006 Apr;13(2):129-40. Review. PubMed PMID: 16735987.

293: Becker JC, Muller-Tidow C, Serve H, Domschke W, Pohle T. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J

Gastroenterol. 2006 Jun 7;12(21):3297-305. Review. PubMed PMID: 16733844.

294: Bdair FM, Graham SP, Smith PF, Javle MM. Gemcitabine and acute myocardial infarction--a case report. Angiology. 2006 May-Jun;57(3):367-71. Review. PubMed PMID: 16703198.

295: Borner MM. [Molecular targets in colon cancer]. Ther Umsch. 2006 Apr;63(4):243-8. Review. German. PubMed PMID: 16689454.

296: Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2006 May 10;24(14):2158-63. Review. PubMed PMID: 16682734.

297: Raz DJ, He B, Rosell R, Jablons DM. Bronchioloalveolar carcinoma: a review.

Clin Lung Cancer. 2006 Mar;7(5):313-22. Review. PubMed PMID: 16640802.

298: Kawase I. [Present status of and new trends in therapy for lung cancer]. Nippon Naika Gakkai Zasshi. 2006 Mar 10;95(3):529-33. Review. Japanese. PubMed PMID: 16640087.

299: Moody TW. Peptide hormones and lung cancer. Panminerva Med. 2006 Mar;48(1):19-26. Review. PubMed PMID: 16633328.

300: Sipples R. Common side effects of anti-EGFR therapy: acneform rash. Semin Oncol Nurs. 2006 Feb;22(1 Suppl 1):28-34. Review. PubMed PMID: 16616284.

301: Fish-Steagall A, Searcy P, Sipples R. Clinical experience with anti-EGFR therapy. Semin Oncol Nurs. 2006 Feb;22(1 Suppl 1):10-9. Review. PubMed PMID: 16616282.

302: Cersosimo RJ. Gefitinib: an adverse effects profile. Expert Opin Drug Saf. 2006 May;5(3):469-79. Review. PubMed PMID: 16610973.

303: Cascone T, Morelli MP, Ciardiello F. Small molecule epidermal growth factor

receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. Ann Oncol. 2006 Mar;17 Suppl 2:ii46-48. Review. PubMed PMID: 16608981.

304: Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin. 2006 Mar;22(3):561-73. Review. PubMed PMID: 16574039.

305: Huang CL, Yokomise H, Fukushima M, Kinoshita M. Tailor-made chemotherapy for non-small cell lung cancer patients. Future Oncol. 2006 Apr;2(2):289-99. Review.

PubMed PMID: 16563096.

306: Saba NF, Khuri FR, Shin DM. Targeting the epidermal growth factor receptor.

Trials in head and neck and lung cancer. Oncology (Williston Park). 2006 Feb;20(2):153-61; discussion 162, 166, 169 passim. Review. PubMed PMID: 16562649.

307: Lynch T Jr, Kim E. Optimizing chemotherapy and targeted agent combinations in NSCLC. Lung Cancer. 2005 Dec;50 Suppl 2:S25-32. Review. PubMed PMID: 16557671.

308: Rigas JR, Lara PN Jr. Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer. Lung Cancer. 2005 Dec;50 Suppl 2:S17-24. Review. PubMed PMID: 16557670.

309: Riedel RF, Febbo PG. Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. Future Oncol. 2005 Aug;1(4):461-6. Review. PubMed PMID: 16556022.

310: Ciardiello F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol. 2005 Apr;1(2):221-34. Review. PubMed PMID: 16555994.

311: Katoh M, Katoh M. Bioinformatics for cancer management in the post-genome era. Technol Cancer Res Treat. 2006 Apr;5(2):169-75. Review. PubMed PMID: 16551136.

312: Maione P, Gridelli C, Troiani T, Ciardiello F. Combining targeted therapies

and drugs with multiple targets in the treatment of NSCLC. Oncologist. 2006 Mar;11(3):274-84. Review. PubMed PMID: 16549812.

313: Hennemann B. [Palliative chemotherapy of head and neck cancer: present status and future development]. Laryngorhinootologie. 2006 Mar;85(3):172-8. Review. German. PubMed PMID: 16547892.

314: Buschbeck M. Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer. Drugs R D. 2006;7(2):73-86. Review. PubMed PMID: 16542054.

315: Uramoto H, Kagami S, Iwashige A, Tsukada J. [Chemotherapy for lung cancer patients]. J UOEH. 2006 Mar 1;28(1):75-84. Review. Japanese. PubMed PMID: 16541742.

316: Cappuzzo F, Finocchiaro G, Metro G, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L. Clinical experience with gefitinib: an update. Crit Rev Oncol Hematol. 2006 Apr;58(1):31-45. Epub 2006 Mar 13. Review. PubMed PMID: 16531062.

317: Eckhardt S. Molecular targeted therapy: a strategy of disillusions or optimism? J Lab Clin Med. 2006 Mar;147(3):108-13. Review. PubMed PMID: 16503239.

318: Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol. 2006;7(1):45-63. Review. PubMed PMID: 16489842.

319: Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev. 2006 Apr;32(2):74-89. Epub 2006 Feb 20. Review. PubMed PMID: 16488082.

320: Bellezza I, Bracarda S, Caserta C, Minelli A. Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro. Mol

Genet Metab. 2006 Jun;88(2):114-22. Epub 2006 Feb 17. Review. PubMed PMID: 16487738.

321: Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, Cairncross JG; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist. 2006 Feb;11(2):165-80. Review. PubMed PMID: 16476837.

322: Edelman MJ, Sekine I, Tamura T, Saijo N. Geographic variation in the second-line treatment of non-small cell lung cancer. Semin Oncol. 2006 Feb;33(1 Suppl 1):S39-44. Review. PubMed PMID: 16472708.

323: Miller VA. Optimizing therapy in previously treated non-small cell lung cancer. Semin Oncol. 2006 Feb;33(1 Suppl 1):S25-31. Review. PubMed PMID: 16472706.

324: de Marinis F, De Santis S, De Petris L. Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies. Semin Oncol. 2006 Feb;33(1 Suppl 1):S17-24. Review. PubMed PMID: 16472705.

325: Massarelli E, Herbst RS. Use of novel second-line targeted therapies in non-small cell lung cancer. Semin Oncol. 2006 Feb;33(1 Suppl 1):S9-16. Review. PubMed PMID: 16472704.

326: Cullen M. Second-line treatment options in advanced non-small cell lung cancer: current status. Semin Oncol. 2006 Feb;33(1 Suppl 1):S3-8. Review. PubMed

PMID: 16472703.

327: Reck M, Kranich AL, Steinbach AK, Gatzemeier U. [EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer]. Med Klin (Munich). 2005 Dec 15;100(12):785-93. Review. German. PubMed PMID: 16453093.

328: Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol. 2006 Jun;58(3):242-56. Epub 2006 Jan 24. Review. PubMed PMID: 16436330.

329: Buter J, Giaccone G. EGFR inhibitors in lung cancer. Oncology (Williston Park). 2005 Nov;19(13):1707-11; discussion 1711-2, 1720-3. Review. PubMed PMID: 16425523.

330: Adenis A, Hebbar M. [Targeting the epidermal growth factor receptor in colorectal cancer: clinical results]. Bull Cancer. 2005 Aug;92(Spec no):S21-8. Review. French. PubMed PMID: 16387666.

331: Milano G. [Pharmacological skills for targeting EGFR and VEGF]. Bull Cancer. 2005 Aug;92(Spec no):S17-20. Review. French. PubMed PMID: 16387665.

332: Harari PM, Huang S. Radiation combined with EGFR signal inhibitors: head and neck cancer focus. Semin Radiat Oncol. 2006 Jan;16(1):38-44. Review. PubMed PMID: 16378905.

333: Nicolini A, Carpi A, Tarro G. Biomolecular markers of breast cancer. Front Biosci. 2006 May 1;11:1818-43. Review. PubMed PMID: 16368559.

334: Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy. Eur J Cancer. 2006

Jan;42(1):17-23. Review. PubMed PMID: 16364841.

335: Vanhoefer U. Molecular mechanisms and targeting of colorectal cancer. Semin

Oncol. 2005 Dec;32(6 Suppl 8):7-10. Review. PubMed PMID: 16360005.

336: Silvestri GA, Rivera MP. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest. 2005 Dec;128(6):3975-84. Review. PubMed PMID: 16354869.

337: Reddy GK. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.

Clin Lung Cancer. 2005 Nov;7(3):163-5. Review. PubMed PMID: 16354309.

338: Khosravi Shahi P, Díaz Muñoz de la Espada VM. [Pancreatic adenocarcinoma: therapeutical update]. An Med Interna. 2005 Aug;22(8):390-4. Review. Spanish. PubMed PMID: 16351494.

339: West H. Emerging approaches to advanced bronchioloalveolar carcinoma. Curr Treat Options Oncol. 2006 Jan;7(1):69-76. Review. PubMed PMID: 16343370.

340: Chai RL, Grandis JR. Advances in molecular diagnostics and therapeutics in head and neck cancer. Curr Treat Options Oncol. 2006 Jan;7(1):3-11. Review. PubMed PMID: 16343364.

341: Quoix E, Mennecier B. [Lung cancer in women]. Rev Mal Respir. 2005 Dec;22(6

Pt 2):8S55-62. Review. French. PubMed PMID: 16340837.

342: Kuo T, Fisher GA. Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer. Clin

Colorectal Cancer. 2005 Nov;5 Suppl 2:S62-70. Review. PubMed PMID: 16336751.

343: Taube SE, Jacobson JW, Lively TG. Cancer diagnostics: decision criteria for

marker utilization in the clinic. Am J Pharmacogenomics. 2005;5(6):357-64. Review. PubMed PMID: 16336001.

344: Penne K, Bohlin C, Schneider S, Allen D. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. Cancer Nurs. 2005 Nov-Dec;28(6):481-6. Review. PubMed PMID: 16330971.

345: Scagliotti G. An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer. Expert Opin Pharmacother. 2005 Dec;6(16):2855-66. Review. PubMed PMID: 16318436.

346: Ramalingam S, Belani CP. Molecularly-targeted therapies for non-small cell lung cancer. Expert Opin Pharmacother. 2005 Dec;6(15):2667-79. Review. PubMed PMID: 16316305.

347: Staehler M, Rohrmann K, Haseke N, Stief CG, Siebels M. Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets. 2005 Nov;6(7):835-46. Review. PubMed PMID: 16305462.

348: Yanase K, Tsukahara S, Mitsuhashi J, Sugimoto Y. Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. Cancer Lett. 2006 Mar 8;234(1):73-80. Epub 2005 Nov 21. Review. PubMed PMID: 16303243.

349: Guren TK, Christoffersen T, Thoresen GH, Wisløff F, Dajani O, Tveit KM. [Antineoplastic agents targeting tyrosine kinases]. Tidsskr Nor Laegeforen. 2005

Nov 17;125(22):3115-9. Review. Norwegian. PubMed PMID: 16299568.

350: Akiyama S. [Genetic alterations and chemoresistance]. Gan To Kagaku Ryoho. 2005 Nov;32(12):1895-901. Review. Japanese. PubMed PMID: 16282723.

351: Shimizu J, Horio Y, Mitsudomi T. [Molecular targeted therapy--non-small-cell lung cancer and gefitinib]. Gan To Kagaku Ryoho. 2005 Nov;32(12):1879-85. Review. Japanese. PubMed PMID: 16282720.

352: Kurebayashi J. Resistance to endocrine therapy in breast cancer. Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:39-46. Review. PubMed PMID: 16273353.

353: Ciardiello F, De Vita F. Epidermal growth factor receptor (EGFR) inhibitors

in cancer therapy. Prog Drug Res. 2005;63:93-114. Review. PubMed PMID: 16265878.

354: Dowell JE, Minna JD. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy. Nat Clin Pract Oncol. 2004 Nov;1(1):2-3. Review. PubMed PMID: 16264773.

355: Agelaki S, Georgoulias V. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. Expert Opin Emerg Drugs. 2005 Nov;10(4):855-74. Review. PubMed PMID: 16262567.

356: Herbst RS, Kies MS. Gefitinib: current and future status in cancer therapy.

Clin Adv Hematol Oncol. 2003 Aug;1(8):466-72. Review. PubMed PMID: 16258434.

357: D'Amico TA. Adjuvant chemotherapy for non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2005 Fall;17(3):195-8. Review. PubMed PMID: 16253822.

358: Dowsett M, Nicholson RI, Pietras RJ. Biological characteristics of the pure

antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat. 2005;93 Suppl 1:S11-8. Review. PubMed PMID: 16247595.

359: Stadler WM. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer. 2005 Dec 1;104(11):2323-33. Review. PubMed PMID: 16240452.

360: Kakiuchi S, Yano S, Sone S. [Development of individualized therapy of non-small cell lung cancer targeted at the EGF receptor]. Nippon Naika Gakkai Zasshi. 2005 Sep 10;94(9):1831-8. Review. Japanese. PubMed PMID: 16223143.

361: Okamura T, Kurisu K. [Molecular targeted therapy for malignant brain tumors]. Nippon Rinsho. 2005 Sep;63 Suppl 9:520-6. Review. Japanese. PubMed PMID: 16201575.

362: Nemenoff RA, Winn RA. Role of nuclear receptors in lung tumourigenesis. Eur

J Cancer. 2005 Nov;41(16):2561-8. Epub 2005 Sep 30. Review. PubMed PMID: 16199155.

363: Howell A. The future of fulvestrant ("Faslodex"). Cancer Treat Rev. 2005;31

Suppl 2:S26-33. Epub 2005 Sep 28. Review. PubMed PMID: 16198056.

364: Klebl BM, Müller G. Second-generation kinase inhibitors. Expert Opin Ther Targets. 2005 Oct;9(5):975-93. Review. PubMed PMID: 16185153.

365: Gurpide A, Perez-Gracia JL, Lopez-Picazo JM, Moreno M, Zubieta JL, Martin-Algarra S, Garcia-Foncillas J. Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature. Clin Lung Cancer. 2005 Sep;7(2):138-40. Review. PubMed PMID: 16179102.

366: Lee D. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer. Clin Lung Cancer. 2005 Sep;7(2):89-91. Review. PubMed PMID: 16179094.

367: Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist. 2005 Sep;10(8):579-89. Review. PubMed PMID: 16177282.

368: Cooney MM, Remick SC, Vogelzang NJ. Novel agents for the treatment of advanced kidney cancer. Clin Adv Hematol Oncol. 2004 Oct;2(10):664-70. Review. PubMed PMID: 16163253.

369: Edelman MJ. Second-line chemotherapy and beyond for non-small-cell lung cancer. Clin Adv Hematol Oncol. 2004 Jun;2(6):373-8. Review. PubMed PMID: 16163207.

370: Johnson BE, Jänne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 2005 Sep 1;65(17):7525-9. Review. PubMed PMID: 16140912.

371: Cappuzzo F, Finocchiaro G, Trisolini R, Toschi L, Bartolini S, Metro G, Crinò L. Perspectives on salvage therapy for non-small-cell lung cancer. Oncology (Williston Park). 2005 Jul;19(8):989-95; discussion 995-6, 999, 1003-4, passim. Review. PubMed PMID: 16131043.

372: Ganti AK, Potti A. Epidermal growth factor inhibition in solid tumours. Expert Opin Biol Ther. 2005 Sep;5(9):1165-74. Review. PubMed PMID: 16120047.

373: Spicer J, Harper P. Targeted therapies for non-small cell lung cancer. Int J Clin Pract. 2005 Sep;59(9):1055-62. Review. PubMed PMID: 16115182.

374: Wakeling AE. Inhibitors of growth factor signalling. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S183-7. Review. PubMed PMID: 16113095.

375: Jones HE, Gee JM, Taylor KM, Barrow D, Williams HD, Rubini M, Nicholson RI.

Development of strategies for the use of anti-growth factor treatments. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S173-82. Review. PubMed PMID: 16113094.

376: Johnston SR. Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S145-57. Review. PubMed PMID: 16113091.

377: Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S135-44. Review. PubMed PMID: 16113090.

378: Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, Martin LA,

Ciardiello F, Miller WR, Dowsett M, Barrett-Lee P, Robertson JF, Johnston SR, Jones HE, Wakeling AE, Duncan R, Nicholson RI. Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer. 2005 Jul;12

Suppl 1:S1-7. Review. PubMed PMID: 16113086.

379: Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J. Breast cancer resistance

protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci. 2005 Aug;96(8):457-65. Review. PubMed PMID: 16108826.

380: Krupnick AS, Kreisel D, Hope A, Bradley J, Govindan R, Meyers B. Recent advances and future perspectives in the management of lung cancer. Curr Probl Surg. 2005 Aug;42(8):540-610. Review. PubMed PMID: 16087000.

381: Comis RL. The current situation: erlotinib (Tarceva) and gefitinib (Iressa)

in non-small cell lung cancer. Oncologist. 2005 Aug;10(7):467-70. Review. PubMed

PMID: 16079313.

382: Raizer JJ. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol. 2005 Aug;74(1):77-86. Review. PubMed PMID: 16078112.

383: Engelman JA, Jänne PA. Factors predicting response to EGFR tyrosine kinase inhibitors. Semin Respir Crit Care Med. 2005 Jun;26(3):314-22. Review. PubMed PMID: 16052433.

384: Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005 Aug 1;23(22):5235-46. Review. PubMed PMID: 16051966.

385: Ready N. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. Semin Oncol.

2005 Apr;32(2 Suppl 3):S35-41. Review. PubMed PMID: 16015534.

386: Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005 Dec;315(3):971-9. Epub 2005 Jul 7. Review. PubMed PMID:

16002463.

387: Isobe T, Herbst RS, Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol. 2005 Jun;32(3):315-28. Review. PubMed PMID: 15988686.

388: Yokoba M, Yanase N, Masuda N. [New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents]. Gan To Kagaku Ryoho. 2005 Jun;32(6):783-8. Review. Japanese. PubMed PMID: 15984516.

389: Ueoka H. [Chemotherapy for advanced non-small cell lung cancer]. Gan To Kagaku Ryoho. 2005 Jun;32(6):770-6. Review. Japanese. PubMed PMID: 15984514.

390: Kosaka T, Endoh H, Yatabe Y, Mitsudomi T. [Translational research on lung cancer--EGFR gene mutation]. Gan To Kagaku Ryoho. 2005 Jun;32(6):750-8. Review. Japanese. PubMed PMID: 15984511.

391: Buter J, Giaccone G. Medical treatment of non-small-cell lung cancer. Ann Oncol. 2005;16 Suppl 2:ii229-32. Review. PubMed PMID: 15958463.

392: Tamura K, Fukuoka M. Gefitinib in non-small cell lung cancer. Expert Opin Pharmacother. 2005 Jun;6(6):985-93. Review. PubMed PMID: 15952926.

393: Zhang Z, Li M, Rayburn ER, Hill DL, Zhang R, Wang H. Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases. Am J Pharmacogenomics. 2005;5(3):173-90. Review. PubMed PMID: 15952871.

394: Speake G, Holloway B, Costello G. Recent developments related to the EGFR as a target for cancer chemotherapy. Curr Opin Pharmacol. 2005 Aug;5(4):343-9. Review. PubMed PMID: 15950538.

395: Byrne BJ, Garst J. Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. Curr Oncol Rep. 2005 Jul;7(4):241-7. Review.

PubMed PMID: 15946581.

396: Reddy GK. Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer. Clin

Lung Cancer. 2005 May;6(6):338-9. Review. PubMed PMID: 15943892.

397: Kelland LR. Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2005 May;10(2):413-24. Review. PubMed PMID: 15934876.

398: Grimm CF, Blum HE, Geissler M. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives]. Dtsch Med Wochenschr. 2005 Jun 10;130(23):1438-42. Review. German. PubMed PMID: 15929020.

399: Heymach JV. ZD6474--clinical experience to date. Br J Cancer. 2005 Jun;92 Suppl 1:S14-20. Review. PubMed PMID: 15928653; PubMed Central PMCID: PMC2362057.

400: Gasparini G, Longo R, Torino F, Morabito A. Therapy of breast cancer with molecular targeting agents. Ann Oncol. 2005 May;16 Suppl 4:iv28-36. Review. PubMed PMID: 15923426.

401: Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and

characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005 Jul 8;225(1):1-26. Epub 2004 Nov 11. Review. PubMed PMID: 15922853.

402: Dei Tos AP, Ellis I. Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? Eur J Cancer. 2005 Jul;41(10):1383-92. Review. PubMed PMID: 15919198.

403: Oka M, Fukuda M, Soda H. [Anticancer drugs and ABC transporters]. Gan To Kagaku Ryoho. 2005 May;32(5):585-92. Review. Japanese. PubMed PMID: 15918555.

404: Magné N, Milano G. [Targeted therapies: last focus on EGF receptor inhibitors in breast cancer]. Bull Cancer. 2004 Dec 1;91 Suppl 4:S257-60. Review. French. PubMed PMID: 15899618.

405: Di Maio M, Gridelli C, Normanno N, Perrone F, Ciardiello F. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Cell Physiol. 2005 Dec;205(3):355-63. Review. PubMed PMID: 15895392.

406: Fallowfield LJ, Harper P. Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer. 2005 Jun;48(3):365-77. Epub 2005 Jan 26. Review. PubMed PMID: 15893006.

407: Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets. 2005 May;5(3):171-93. Review. PubMed PMID: 15892618.

408: Mancuso A, Sternberg CN. Colorectal cancer and antiangiogenic therapy: what

can be expected in clinical practice? Crit Rev Oncol Hematol. 2005 Jul;55(1):67-81. Review. PubMed PMID: 15890525.

409: Miller VA, Hirsch FR, Johnson DH. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. J Clin Oncol. 2005 May 10;23(14):3288-93. Review. PubMed PMID: 15886316.

410: Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of

non-small-cell lung cancer. J Clin Oncol. 2005 May 10;23(14):3235-42. Review. PubMed PMID: 15886311.

411: Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 2005 May 10;23(14):3227-34. Review. PubMed PMID: 15886310.

412: Vallbohmer D, Lenz HJ. Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S19-27. Review. PubMed PMID: 15871762.

413: Tagliaferri P, Tassone P, Blotta S, Viscomi C, Grillone F, Budillon A, Caraglia M, Venuta S. Antitumor therapeutic strategies based on the targeting of

epidermal growth factor-induced survival pathways. Curr Drug Targets. 2005 May;6(3):289-300. Review. PubMed PMID: 15857289.

414: Albanell J, Gascón P. Small molecules with EGFR-TK inhibitor activity. Curr

Drug Targets. 2005 May;6(3):259-74. Review. PubMed PMID: 15857287.

415: Pal SK, Pegram M. Epidermal growth factor receptor and signal transduction:

potential targets for anti-cancer therapy. Anticancer Drugs. 2005 Jun;16(5):483-94. Review. PubMed PMID: 15846113.

416: Lau D, Seibert A, Gandara D, Laptalo L, Geraghty E, Coulon C. Computer-assisted image analysis of bronchioloalveolar carcinoma. Clin Lung Cancer. 2005 Mar;6(5):281-6. Review. PubMed PMID: 15845178.

417: Frampton JE, Easthope SE. Spotlight on gefitinib in non-small-cell lung cancer. Am J Pharmacogenomics. 2005;5(2):133-6. Review. PubMed PMID: 15813676.

418: López JI, Colby TV, Gazdar AF. Current status of small peripheral adenocarcinomas of the lung and their importance to pathologists. Ann Diagn Pathol. 2005 Apr;9(2):115-22. Review. PubMed PMID: 15806521.

419: [Molecular target therapy for malignant tumors]. Nippon Naika Gakkai Zasshi. 2005 Feb 20;94 Suppl:76-80. Review. Japanese. PubMed PMID: 15796061.

420: Knuuttila A, Karjalainen EM, Rouhos A, Mali P. [Gefitinib as targeted treatment for non-small-cell lung cancer]. Duodecim. 2005;121(3):267-72. Review.

Finnish. PubMed PMID: 15787284.

421: Yatabe Y. [Molecular diagnosis of solid tumors]. Nippon Rinsho. 2005 Mar;63(3):434-40. Review. Japanese. PubMed PMID: 15773342.

422: Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005 Apr 10;23(11):2556-68. Epub 2005 Mar 14. Review. PubMed PMID: 15767641.

423: Blay JY, Le Cesne A, Alberti L, Ray-Coquart I. Targeted cancer therapies. Bull Cancer. 2005 Feb;92(2):E13-8. Review. PubMed PMID: 15749638.

424: Kaplow R. Innovations in antineoplastic therapy. Nurs Clin North Am. 2005 Mar;40(1):77-94. Review. PubMed PMID: 15733948.

425: Reck M, Gatzemeier U. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer. Respir Med. 2005 Mar;99(3):298-307. Review. PubMed PMID: 15733505.

426: Zielinski CC. [Impact of oncologic therapeutic concepts 2004]. Acta Med Austriaca. 2004;31(4):139-43. Review. German. PubMed PMID: 15732250.

427: Lockhart AC, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol. 2005 Feb;32(1):52-60. Review. Erratum in: Semin Oncol. 2005 Aug;32(4):432. Lockhart, Craig [corrected to Lockhart, A Craig]. PubMed PMID: 15726506.

428: Perrone F, Di Maio M, Budillon A, Normanno N. Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical

trials. Curr Opin Oncol. 2005 Mar;17(2):123-9. Review. PubMed PMID: 15725916.

429: Hirsch FR, Witta S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol. 2005 Mar;17(2):118-22. Review. PubMed PMID: 15725915.

430: Price N, Belani C. Clinical development of gefitinib in non-small-cell lung

cancer and the Iressa Survival Evaluation in Lung Cancer trial. Clin Lung Cancer. 2005 Jan;6(4):214-6. Review. PubMed PMID: 15694012.

431: Robertson JF, Come SE, Jones SE, Beex L, Kaufmann M, Makris A, Nortier JW, Possinger K, Rutqvist LE. Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer. 2005 Feb;41(3):346-56. Review. PubMed PMID: 15691633.

432: Danson S, Blackhall F, Hulse P, Ranson M. Interstitial lung disease in lung

cancer: separating disease progression from treatment effects. Drug Saf. 2005;28(2):103-13. Review. PubMed PMID: 15691221.

433: Ardizzoni A, Tiseo M. Second-line chemotherapy in the treatment of advanced

non-small cell lung cancer (NSCLC). J Chemother. 2004 Nov;16 Suppl 4:104-7. Review. PubMed PMID: 15688623.

434: Vidal L, Attard G, Kaye S, De Bono J. Reversing resistance to targeted therapy. J Chemother. 2004 Nov;16 Suppl 4:7-12. Review. PubMed PMID: 15688600.

435: Akita H. [Second-line treatment for advanced non-small-cell lung cancers]. Gan To Kagaku Ryoho. 2005 Jan;32(1):15-8. Review. Japanese. PubMed PMID: 15675575.

436: Blagosklonny MV. How cancer could be cured by 2015. Cell Cycle. 2005 Feb;4(2):269-78. Epub 2005 Feb 21. Review. PubMed PMID: 15655345.

437: Lilenbaum RC. Treatment of patients with advanced lung cancer and poor performance status. Clin Lung Cancer. 2004 Dec;6 Suppl 2:S71-4. Review. PubMed PMID: 15638962.

438: Herbst RS, Sandler AB. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer. 2004 Dec;6 Suppl 1:S7-S19. Review. PubMed PMID: 15638959.

439: Patel JD. Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma. Clin Lung Cancer. 2004

Dec;6 Suppl 1:S43-7. Review. PubMed PMID: 15638957.

440: Fuster LM, Sandler AB. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. Clin Lung Cancer. 2004 Dec;6 Suppl 1:S24-9. Review. PubMed PMID: 15638954.

441: Sanson M, Thillet J, Hoang-Xuan K. Molecular changes in gliomas. Curr Opin Oncol. 2004 Nov;16(6):607-13. Review. PubMed PMID: 15627025.

442: Loi S, Buyse M, Sotiriou C, Cardoso F. Challenges in breast cancer clinical

trial design in the postgenomic era. Curr Opin Oncol. 2004 Nov;16(6):536-41. Review. PubMed PMID: 15627014.

443: Madelaine J, Cadranel J, Zalcman G. [Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting.].

Rev Mal Respir. 2004 Nov;21(5 Pt 1):881-5. Review. French. PubMed PMID: 15622331.

444: Carpentier AF. Neuro-oncology: the growing role of chemotherapy in glioma. Lancet Neurol. 2005 Jan;4(1):4-5. Review. PubMed PMID: 15620846.

445: Ohe Y. Chemoradiotherapy for lung cancer: current status and perspectives. Int J Clin Oncol. 2004 Dec;9(6):435-43. Review. PubMed PMID: 15616873.

446: Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004 Dec;11(4):689-708. Review. PubMed PMID: 15613446.

447: Fong KM, Bowman R. A molecular chink in the lung cancer armour. Respirology. 2004 Nov;9(4):426-7. Review. PubMed PMID: 15612952.

448: Birnbaum A, Ready N. Gefitinib therapy for non-small cell lung cancer. Curr

Treat Options Oncol. 2005 Jan;6(1):75-81. Review. PubMed PMID: 15610717.

449: Tanović A, Alfaro V. Gefitinib: current status in the treatment of non-small cell lung cancer. Drugs Today (Barc). 2004 Oct;40(10):809-27. Review. PubMed PMID: 15605116.

450: Fanucchi M, Khuri FR. Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol. 2004 Dec;31(6):809-15. Review. PubMed PMID: 15599859.

451: Amato RJ. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol. 2005 Jan;16(1):7-15. Review. PubMed PMID: 15598929.

452: Nakanishi Y. [Does molecular targeted therapy change the treatment for lung

cancer?]. Fukuoka Igaku Zasshi. 2004 Sep;95(9):205-9. Review. Japanese. PubMed PMID: 15584345.

453: Von Pawel J. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bull Cancer. 2004 May 1;91(5):E70-6. Review. PubMed PMID: 15582898.

454: Herbst RS, Fukuoka M, Baselga J. Gefitinib--a novel targeted approach to treating cancer. Nat Rev Cancer. 2004 Dec;4(12):956-65. Review. PubMed PMID: 15573117.

455: Adachi Y, Lee CT, Carbone DP. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy. Novartis Found Symp. 2004;262:177-89; discussion 190-2, 265-8. Review. PubMed PMID: 15562829.

456: Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer. Drug Saf. 2004;27(14):1081-92. Review. PubMed PMID: 15554744.

457: Korfee S, Gauler T, Hepp R, Pöttgen C, Eberhardt W. New targeted treatments

in lung cancer--overview of clinical trials. Lung Cancer. 2004 Aug;45 Suppl 2:S199-208. Review. PubMed PMID: 15552800.

458: Poon AN, Ho SS, Yeo W, Mok TS. Brain metastasis responding to gefitinib alone. Oncology. 2004;67(2):174-8. Review. PubMed PMID: 15539923.

459: Bréchot JM. [The place of targeted treatments: receptor tyrosine kinase inhibitors]. Rev Pneumol Clin. 2004 Nov;60(5 Pt 2):3S68-71. Review. French. PubMed PMID: 15536357.

460: Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN. Targeted therapies for cancer 2004. Am J Clin Pathol. 2004 Oct;122(4):598-609. Review. PubMed PMID: 15487459.

461: Frampton JE, Easthope SE. Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer. Drugs. 2004;64(21):2475-92. Review. PubMed PMID: 15482004.

462: Namba Y, Kijima T, Yokota S, Niinaka M, Kawamura S, Iwasaki T, Takeda Y, Kimura H, Okada T, Yamaguchi T, Nakagawa M, Okumura Y, Maeda H, Ito M. Gefitinib

in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer. 2004 Sep;6(2):123-8. Review. PubMed PMID: 15476598.

463: Pizzo B. New directions in oncology nursing care: focus on gefitinib in patients with lung cancer. Clin J Oncol Nurs. 2004 Aug;8(4):385-92. Review. PubMed PMID: 15354925.

464: Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer. 2004 Aug;91 Suppl 2:S18-23. Review. PubMed PMID: 15340374;

PubMed Central PMCID: PMC2750811.

465: Onn A, Tsuboi M, Thatcher N. Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib. Br J Cancer. 2004 Aug;91 Suppl 2:S11-7. Review. PubMed PMID: 15340373; PubMed Central

PMCID: PMC2750809.

466: Herbst RS. EGFR inhibition in NSCLC: the emerging role of cetuximab. J Natl

Compr Canc Netw. 2004 Sep;2 Suppl 2:S41-51. Review. PubMed PMID: 19780245.

467: Di Cosimo S, Ferretti G, Milella M, Martinelli E, Alimonti A, Papaldo P, Carlini P, Fabi A, Matar P, Cognetti F. [Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)]. Minerva Med. 2004 Jun;95(3):233-41. Review. Italian. PubMed PMID: 15289751.

468: Nishio K. [Resistance to target-based therapy and its circumvention]. Nippon Rinsho. 2004 Jul;62(7):1343-7. Review. Japanese. PubMed PMID: 15283154.

469: Nakagawa K. [Gefitinib in non-small cell lung cancer]. Nippon Rinsho. 2004 Jul;62(7):1312-20. Review. Japanese. PubMed PMID: 15283149.

470: Akiyama S. [The mechanisms of the resistance to molecular targeting agents]. Nippon Rinsho. 2004 Jul;62(7):1297-304. Review. Japanese. PubMed PMID: 15283147.

471: Rogers SJ, Harrington KJ, Eccles SA, Nutting CM. Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC. Expert Rev

Anticancer Ther. 2004 Aug;4(4):569-83. Review. PubMed PMID: 15270661.

472: Wolf M, Swaisland H, Averbuch S. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res. 2004 Jul 15;10(14):4607-13. Review. PubMed PMID: 15269131.

473: Zhang L, Cheng ZW, Gao JM. [New advance of the molecular targeting agents in advanced non-small cell lung cancer]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004 Jun;26(3):323-9. Review. Chinese. PubMed PMID: 15266840.

474: Price DK, Figg WD. Mutations in the EGFR: the importance of genotyping. Cancer Biol Ther. 2004 May;3(5):434-5. Epub 2004 May 20. Review. PubMed PMID: 15254431.

475: El-Rayes BF, LoRusso PM. Targeting the epidermal growth factor receptor. Br

J Cancer. 2004 Aug 2;91(3):418-24. Review. PubMed PMID: 15238978; PubMed Central

PMCID: PMC2409851.

476: Capriotti T. New oncology strategy: molecular targeting of cancer cells. Medsurg Nurs. 2004 Jun;13(3):191-5. Review. PubMed PMID: 15219169.

477: Khuri FR, Cohen V. Molecularly targeted approaches to the chemoprevention of lung cancer. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4249s-4253s. Review. PubMed PMID: 15217968.

478: Giaccone G. The role of gefitinib in lung cancer treatment. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4233s-4237s. Review. PubMed PMID: 15217964.

479: Gandara DR, West H, Chansky K, Davies AM, Lau DH, Crowley J, Gumerlock PH, Hirsch FR, Franklin WA. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4205s-4209s. Review. PubMed PMID: 15217959.

480: Purdom M. Management of acneiform rashes related to gefitinib therapy. Clin

J Oncol Nurs. 2004 Jun;8(3):316-7. Review. PubMed PMID: 15208829.

481: Maione P, Rossi A, Airoma G, Ferrara C, Castaldo V, Gridelli C. The role of

targeted therapy in non-small cell lung cancer. Crit Rev Oncol Hematol. 2004 Jul;51(1):29-44. Review. PubMed PMID: 15207252.

482: Natale RB. Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer. Semin Oncol. 2004 Jun;31(3 Suppl 9):23-30. Review. PubMed PMID: 15206079.

483: Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magné N, Milano G.

Pharmacological background of EGFR targeting. Ann Oncol. 2004 Jul;15(7):1007-12.

Review. PubMed PMID: 15205192.

484: Blagosklonny MV. Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers. Cancer Biol Ther. 2004 May;3(5):436-40. Epub 2004 May 20. Review. PubMed PMID: 15197345.

485: Prommer E. Gefitinib: a new agent in palliative care. Am J Hosp Palliat Care. 2004 May-Jun;21(3):222-7. Review. PubMed PMID: 15188923.

486: Patel JD, Pasche B, Argiris A. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Crit Rev Oncol Hematol. 2004 Jun;50(3):175-86. Review. PubMed PMID: 15182824.

487: Stabile LP, Siegfried JM. Estrogen receptor pathways in lung cancer. Curr Oncol Rep. 2004 Jul;6(4):259-67. Review. PubMed PMID: 15161576.

488: Cersosimo RJ. Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer. Am J Health Syst Pharm. 2004 May 1;61(9):889-98. Review. PubMed PMID: 15156965.

489: Dancey JE. Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow. Cancer Cell. 2004 May;5(5):411-5. Review. PubMed PMID: 15144948.

490: Natale RB. Epidermal growth factor receptor-targeted therapy with ZD1839: symptom improvement in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys.

2004;59(2 Suppl):39-43. Review. PubMed PMID: 15142633.

491: Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat

Oncol Biol Phys. 2004;59(2 Suppl):21-6. Review. PubMed PMID: 15142631.

492: Kim DW, Choy H. Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):11-20. Review. PubMed PMID: 15142630.

493: Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the

treatment of colorectal cancer: a promise fulfilled? Oncology (Williston Park). 2004 Apr;18(4):479-88; discussion 488, 493, 497 passim. Review. PubMed PMID: 15134356.

494: Kaklamani V, O'Regan RM. New targeted therapies in breast cancer. Semin Oncol. 2004 Apr;31(2 Suppl 4):20-5. Review. PubMed PMID: 15124130.

495: Krozely P. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors. Clin J Oncol Nurs. 2004 Apr;8(2):163-8. Review. PubMed PMID: 15108418.

496: Hussar DA. New drugs of 2003. J Am Pharm Assoc (2003). 2004 Mar-Apr;44(2):168-206; quiz 207-10. Review. PubMed PMID: 15098851.

497: Hu B, Wei YQ. [Tumor biotherapy based on epidermal growth factor receptor as a target]. Ai Zheng. 2004 Apr;23(4):471-5. Review. Chinese. PubMed PMID: 15087042.

498: Ciardiello F, De Vita F, Orditura M, Tortora G. The role of EGFR inhibitors

in nonsmall cell lung cancer. Curr Opin Oncol. 2004 Mar;16(2):130-5. Review. PubMed PMID: 15075904.

499: McHugh LA, Griffiths TR, Kriajevska M, Symonds RP, Mellon JK. Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer. Urology. 2004 Apr;63(4):619-24.

Review. PubMed PMID: 15072863.

500: Caponigro F, Ionna F, Comella G. New cytotoxic and molecular-targeted therapies of head and neck tumors. Curr Opin Oncol. 2004 May;16(3):225-30. Review. PubMed PMID: 15069317.

501: Ranson M, Wardell S. Gefitinib, a novel, orally administered agent for the treatment of cancer. J Clin Pharm Ther. 2004 Apr;29(2):95-103. Review. PubMed PMID: 15068398.

502: Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev. 2004 May;30(3):255-68. Review. PubMed PMID: 15059649.

503: Caponigro F. Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer. Anticancer Drugs.

2004 Apr;15(4):311-20. Review. PubMed PMID: 15057134.

504: Shimizu E. [Molecular pathogenesis of lung cancers and the preservative therapy]. Nippon Naika Gakkai Zasshi. 2004 Mar 10;93(3):562-8. Review. Japanese.

PubMed PMID: 15052821.

505: Arteaga CL, Truica CI. Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. Semin Oncol. 2004 Feb;31(1 Suppl 3):3-8. Review. PubMed PMID: 15052538.

506: Kim R, Toge T. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents. Surg Today. 2004;34(4):293-303. Review. PubMed PMID: 15052442.

507: Lorenzo GD, Bianco R, Tortora G, Ciardiello F. Involvement of growth factor

receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin Prostate Cancer. 2003

Jun;2(1):50-7. Review. PubMed PMID: 15046685.

508: Tiseo M, Loprevite M, Ardizzoni A. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer. Curr Med Chem Anticancer Agents. 2004 Mar;4(2):139-48. Review. PubMed PMID: 15032719.

509: Thomas M. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer. Cancer Nurs. 2003 Dec;26(6 Suppl):21S-25S. Review. PubMed PMID: 15025409.

510: Leslie WT, Bonomi PD. Novel treatments in non-small cell lung cancer. Hematol Oncol Clin North Am. 2004 Feb;18(1):245-67. Review. PubMed PMID: 15005292.

511: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Jan-Feb;26(1):53-84. Review. PubMed PMID: 14988742.

512: Kelly K, Averbuch S. Gefitinib: phase II and III results in advanced non-small cell lung cancer. Semin Oncol. 2004 Feb;31(1 Suppl 1):93-9. Review. PubMed PMID: 14981586.

513: Glover KY, Perez-Soler R, Papadimitradopoulou VA. A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer. Semin Oncol. 2004 Feb;31(1 Suppl 1):83-92. Review. PubMed PMID: 14981585.

514: Smith JK, Mamoon NM, Duhé RJ. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol Res. 2004;14(4-5):175-225. Review. PubMed PMID: 14977353.

515: Dancey J. Epidermal growth factor receptor inhibitors in clinical development. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):1003-7. Review. PubMed PMID: 14967462.

516: Langer CJ. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):991-1002. Review. PubMed PMID: 14967461.

517: Ochs JS. Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):941-9. Review. PubMed PMID: 14967454.

518: Hamid O. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. J Am Pharm Assoc (2003). 2004 Jan-Feb;44(1):52-8. Review. PubMed PMID: 14965154.

519: Fayette J, Le Chevalier T, Soria JC. [Therapeutic implications of epidermal

growth factor receptor in lung cancer]. Bull Cancer. 2003 Nov;90 Spec No:S233-40. Review. French. PubMed PMID: 14763145.

520: Adenis A, Peyrat JP. [Inhibitors of epidermal growth factor receptor and colorectal cancer]. Bull Cancer. 2003 Nov;90 Spec No:S228-32. Review. French. PubMed PMID: 14763144.

521: Tortochaux J, Aunoble B, Rolhion C, Bourhis J. [Targeting of epidermal growth factor receptor and applications in ORL cancer]. Bull Cancer. 2003 Nov;90

Spec No:S220-7. Review. French. PubMed PMID: 14763143.

522: Azria D, Larbouret C, Robert B, Culine S, Ychou M, Verrelle P, Dubois JB, Pèlegrin A. [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials]. Bull Cancer. 2003 Nov;90 Spec No:S202-12. Review. French. PubMed PMID: 14763141.

523: Pao W, Miller VA, Kris MG. 'Targeting' the epidermal growth factor receptor

tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol. 2004 Feb;14(1):33-40. Review. PubMed PMID: 14757534.

524: Blackledge G, Averbuch S. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72. Review.

PubMed PMID: 14760365; PubMed Central PMCID: PMC2409596.

525: Pérez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist. 2004;9(1):58-67. Review. PubMed PMID: 14755015.

526: Tortora G, Ciardiello F. Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy. Ann N Y Acad Sci. 2003 Dec;1002:236-43. Review. PubMed PMID: 14751838.

527: Vansteenkiste J. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer. Expert Rev Anticancer Ther. 2004 Feb;4(1):5-17. Review. PubMed PMID: 14748652.

528: Kurebayashi J, Okubo S, Yamamoto Y, Sonoo H. Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast Cancer. 2004;11(1):38-41. Review. PubMed PMID: 14718791.

529: Tsukagoshi S, Mikami O. [Development of novel molecular targeted drug, "Iressa", for the treatment of malignant diseases--its basic and clinical studies]. Gan To Kagaku Ryoho. 2003 Dec;30(13):2155-67. Review. Japanese. PubMed

PMID: 14712782.

530: Birner A. Pharmacology of oral chemotherapy agents. Clin J Oncol Nurs. 2003

Nov-Dec;7(6 Suppl):11-9. Review. PubMed PMID: 14705495.

531: Dancey JE. Recent advances of molecular targeted agents: opportunities for imaging. Cancer Biol Ther. 2003 Nov-Dec;2(6):601-9. Review. PubMed PMID: 14688462.

532: Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park). 2003 Nov;17(11 Suppl 12):23-8. Review. PubMed PMID: 14682120.

533: Gatzemeier U. Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer. Oncology (Williston Park). 2003 Nov;17(11 Suppl 12):7-10. Review. PubMed PMID: 14682117.

534: Konecny GE, Wilson CA, Slamon DJ. Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention? J Natl Cancer Inst. 2003

Dec 17;95(24):1813-5. Review. PubMed PMID: 14679144.

535: Herbst RS, Bunn PA Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5813-24. Review. PubMed PMID: 14676101.

536: Rowinsky EK. Signal events: Cell signal transduction and its inhibition in cancer. Oncologist. 2003;8 Suppl 3:5-17. Review. PubMed PMID: 14671224.

537: van der Poel HG. Smart drugs in prostate cancer. Eur Urol. 2004 Jan;45(1):1-17. Review. PubMed PMID: 14667509.

538: Yano S, Kondo K, Yamaguchi M, Richmond G, Hutchison M, Wakeling A, Averbuch

S, Wadsworth P. Distribution and function of EGFR in human tissue and the effect

of EGFR tyrosine kinase inhibition. Anticancer Res. 2003 Sep-Oct;23(5A):3639-50.

Review. PubMed PMID: 14666659.

539: Ciardiello F, De Vita F, Orditura M, De Placido S, Tortora G. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.

Expert Opin Emerg Drugs. 2003 Nov;8(2):501-14. Review. PubMed PMID: 14662002.

540: Katz A, Zalewski P. Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib. Br J Cancer.

2003 Dec;89 Suppl 2:S15-8. Review. PubMed PMID: 14661048; PubMed Central PMCID: PMC2750244.

541: van Zandwijk N. Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. Br J Cancer. 2003 Dec;89 Suppl 2:S9-14. Review. PubMed PMID: 14661047; PubMed Central PMCID: PMC2750242.

542: Janmaat ML, Giaccone G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist. 2003;8(6):576-86. Review. PubMed PMID: 14657536.

543: Vlahovic G, Crawford J. Activation of tyrosine kinases in cancer. Oncologist. 2003;8(6):531-8. Review. PubMed PMID: 14657531.

544: Shiotsu Y. [Current screening for molecular target therapy of cancer]. Gan To Kagaku Ryoho. 2003 Nov;30(12):1863-72. Review. Japanese. PubMed PMID: 14650952.

545: Khuri FR. Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention. Clin Lung Cancer. 2003 Sep;5 Suppl 1:S36-40. Review. PubMed PMID: 14641993.

546: Schiller JH. Adjuvant systemic therapies in early-stage non-small-cell lung

cancer. Clin Lung Cancer. 2003 Sep;5 Suppl 1:S29-35. Review. PubMed PMID: 14641992.

547: Sandler AB. Molecular targeted agents in non-small-cell lung cancer. Clin Lung Cancer. 2003 Sep;5 Suppl 1:S22-8. Review. PubMed PMID: 14641991.

548: Hammond LA. Pharmacokinetic evaluation of gefitinib when administered with chemotherapy. Clin Lung Cancer. 2003 Sep;5 Suppl 1:S18-21. Review. PubMed PMID: 14641990.

549: Natale RB. Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor. Clin Lung Cancer. 2003 Sep;5 Suppl 1:S11-7. Review. PubMed PMID: 14641989.

550: Averbuch SD. The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer. Clin Lung Cancer. 2003 Sep;5 Suppl 1:S5-S10. Review. PubMed PMID: 14641988.

551: Yano S, Yamaguchi M, Dong RP. EGFR tyrosine kinase inhibitor "gefitinib (Iressa)" for cancer therapy. Nippon Yakurigaku Zasshi. 2003 Dec;122(6):491-7. Review. PubMed PMID: 14639003.

552: Blackledge G. Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy. J Urol. 2003 Dec;170(6 Pt

2):S77-83; discussion S83. Review. PubMed PMID: 14610415.

553: Newton HB. Molecular neuro-oncology and development of targeted therapeutic

strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways. Expert Rev Anticancer Ther. 2003 Oct;3(5):595-614. Review. PubMed PMID: 14599084.

554: DeGrendele H. Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.

Clin Lung Cancer. 2003 Sep;5(2):83-5. Review. PubMed PMID: 14596689.

555: Yamada K, Yamamura T, Yamaguchi S. [Angiogenesis and metastasis in colorectal cancer]. Nippon Rinsho. 2003 Sep;61 Suppl 7:97-101. Review. Japanese.

PubMed PMID: 14574863.

556: Liu CY, Seen S. Gefitinib therapy for advanced non-small-cell lung cancer. Ann Pharmacother. 2003 Nov;37(11):1644-53. Review. PubMed PMID: 14565788.

557: Nicholson RI, Gee JM, Knowlden J, McClelland R, Madden TA, Barrow D, Hutcheson I. The biology of antihormone failure in breast cancer. Breast Cancer Res Treat. 2003;80 Suppl 1:S29-34; discussion S35. Review. PubMed PMID: 14535532.

558: Senderowicz AM. Small-molecule cyclin-dependent kinase modulators. Oncogene. 2003 Sep 29;22(42):6609-20. Review. PubMed PMID: 14528286.

559: Abou-Jawde R, Choueiri T, Alemany C, Mekhail T. An overview of targeted treatments in cancer. Clin Ther. 2003 Aug;25(8):2121-37. Review. PubMed PMID: 14512124.

560: Gill S, Thomas RR, Goldberg RM. New targeted therapies in gastrointestinal cancers. Curr Treat Options Oncol. 2003 Oct;4(5):393-403. Review. PubMed PMID: 12941199.

561: Kudoh S, Yoshimura A, Gemma A. [Iressa (gefitinib)]. Gan To Kagaku Ryoho. 2003 Aug;30(8):1079-84. Review. Japanese. PubMed PMID: 12938261.

562: Shepherd FA. Second-line chemotherapy for non-small cell lung cancer. Expert Rev Anticancer Ther. 2003 Aug;3(4):435-42. Review. PubMed PMID: 12934656.

563: Kudo S, Yoshimura A, Genma A. [Non-small cell lung cancer: 2) Epidermal growth factor receptor inhibitor and severe adverse phenomena]. Nippon Naika Gakkai Zasshi. 2003 Jul 10;92(7):1291-5. Review. Japanese. PubMed PMID: 12924276.

564: Muguruma H, Yano S, Sone S. [Non-small cell lung cancer: 1) Molecular-target therapy]. Nippon Naika Gakkai Zasshi. 2003 Jul 10;92(7):1284-90. Review. Japanese. PubMed PMID: 12924275.

565: Manegold C. Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recents results and further strategies. Adv Exp Med Biol. 2003;532:247-52. Review. PubMed PMID: 12908563.

566: Foggi P, Amodio A. [Molecular therapy of breast carcinoma in the advanced phase]. Tumori. 2003 Jul-Aug;89(4 Suppl):189-91. Review. Italian. PubMed PMID: 12903589.

567: Seymour L. Epidermal growth factor receptor inhibitors: an update on their development as cancer therapeutics. Curr Opin Investig Drugs. 2003 Jun;4(6):658-66. Review. PubMed PMID: 12901223.

568: Kelly K. The benefits of achieving stable disease in advanced lung cancer. Oncology (Williston Park). 2003 Jul;17(7):957-63; discussion 963, 968-70. Review. PubMed PMID: 12886865.

569: Bonomi P. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.

Lung Cancer. 2003 Aug;41 Suppl 1:S43-8. Review. PubMed PMID: 12867061.

570: Johnson DH. Gefitinib (Iressa) trials in non-small cell lung cancer. Lung Cancer. 2003 Aug;41 Suppl 1:S23-8. Review. PubMed PMID: 12867059.

571: Raben D, Helfrich B, Ciardiello F, Bunn PA. Understanding the mechanisms of

action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer. 2003 Aug;41 Suppl 1:S15-22. Review. PubMed PMID: 12867058.

572: Johnson DH. Targeted therapy in non-small cell lung cancer: myth or reality. Lung Cancer. 2003 Aug;41 Suppl 1:S3-8. Review. PubMed PMID: 12867056.

573: Dancey JE, Freidlin B. Targeting epidermal growth factor receptor--are we missing the mark? Lancet. 2003 Jul 5;362(9377):62-4. Review. PubMed PMID: 12853203.

574: Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 2003 Jul;4(7):397-406. Review. PubMed PMID: 12850190.

575: Gainet M, Guardiola E, Dufresne A, Pivot X. [Epidermal growth factor receptors (EGFR): a new target for anticancer therapy]. Cancer Radiother. 2003 Jun;7(3):195-9. Review. French. PubMed PMID: 12834777.

576: Khalil MY, Grandis JR, Shin DM. Targeting epidermal growth factor receptor:

novel therapeutics in the management of cancer. Expert Rev Anticancer Ther. 2003

Jun;3(3):367-80. Review. PubMed PMID: 12820779.

577: Grünwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor

receptor for cancer treatment. J Natl Cancer Inst. 2003 Jun 18;95(12):851-67. Review. PubMed PMID: 12813169.

578: Douglass EC. Development of ZD1839 in colorectal cancer. Semin Oncol. 2003 Jun;30(3 Suppl 6):17-22. Review. PubMed PMID: 12802791.

579: Blagosklonny MV, Darzynkiewicz Z. Why Iressa failed: toward novel use of kinase inhibitors (outlook). Cancer Biol Ther. 2003 Mar-Apr;2(2):137-40. Review.

PubMed PMID: 12750551.

580: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Apr;25(3):225-48. Review. PubMed PMID: 12743628.

581: De Marinis F, Nelli F, D'Auria G. EGFR inhibitors: clinical results. Suppl Tumori. 2002 Nov-Dec;1(6):S5-6. Review. PubMed PMID: 12658893.

582: Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 2003 Mar;10(1):1-21. Review. PubMed PMID: 12653668.

583: Yano S, Muguruma H, Sone S. [Molecular targetting therapy for non-small-cell lung neoplasms with EGF-R inhibitors]. Nippon Naika Gakkai Zasshi. 2003 Feb 10;92(2):318-23. Review. Japanese. PubMed PMID: 12652739.

584: Raben D, Bianco C, Helfrich B, Weng E, Ciardiello F, Harari P. Interference

with EGFR signaling: paradigm for improving radiation response in cancer treatment. Expert Rev Anticancer Ther. 2002 Aug;2(4):461-71. Review. PubMed PMID: 12647989.

585: Schiller JH. New directions for ZD1839 in the treatment of solid tumors. Semin Oncol. 2003 Feb;30(1 Suppl 1):49-55. Review. PubMed PMID: 12644984.

586: Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol. 2003 Feb;30(1 Suppl 1):30-8. Review. PubMed PMID: 12644982.

587: Lorusso PM. Phase I studies of ZD1839 in patients with common solid tumors.

Semin Oncol. 2003 Feb;30(1 Suppl 1):21-9. Review. PubMed PMID: 12644981.

588: Sirotnak FM. Studies with ZD1839 in preclinical models. Semin Oncol. 2003 Feb;30(1 Suppl 1):12-20. Review. PubMed PMID: 12644980.

589: Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol. 2003 Feb;30(1 Suppl

1):3-11. Review. PubMed PMID: 12644979.

590: Glisson BS. Recurrent small cell lung cancer: update. Semin Oncol. 2003 Feb;30(1):72-8. Review. PubMed PMID: 12635091.

591: Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer. 2003 Feb;2(4):246-51. Review. PubMed PMID: 12620146.

592: Tamura T. [Molecular-targeted therapy]. Gan To Kagaku Ryoho. 2003 Feb;30(2):198-202. Review. Japanese. PubMed PMID: 12610866.

593: Thomas M. Overview of clinical trials with epidermal growth factor receptor

inhibitors in advanced non-small cell lung cancer. Semin Oncol Nurs. 2002 Nov;18(4 Suppl 4):20-7. Review. PubMed PMID: 12534150.

594: Baselga J, Albanell J. Epithelial growth factor receptor interacting agents. Hematol Oncol Clin North Am. 2002 Oct;16(5):1041-63. Review. PubMed PMID: 12512382.

595: Workman P. Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction. Expert Rev Anticancer Ther. 2002 Dec;2(6):611-4. Review. PubMed PMID: 12503197.

596: Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal

pathway, and inhibitors in non-small cell lung cancer. Semin Oncol. 2002 Oct;29(5 Suppl 14):38-44. Review. PubMed PMID: 12422312.

597: O'dwyer PJ, Benson AB 3rd. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol. 2002 Oct;29(5 Suppl 14):10-7. Review. PubMed PMID: 12422309.

598: Baselga J, Hammond LA. HER-targeted tyrosine-kinase inhibitors. Oncology. 2002;63 Suppl 1:6-16. Review. PubMed PMID: 12422050.

599: Van Zandwijk N, Baas P. Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC. Suppl Tumori. 2002 Jul-Aug;1(4):S37-8. Review. PubMed PMID: 12415815.

600: Scagliotti GV. Tyrosine kinase signal transduction inhibitors. Clinical trials. Suppl Tumori. 2002 Jul-Aug;1(4):S34-6. Review. PubMed PMID: 12415814.

601: Ciardiello F. The rational basis of using novel targeted biological agents in non-small cell lung cancer. Suppl Tumori. 2002 Jul-Aug;1(4):S31-3. Review. PubMed PMID: 12415813.

602: Culy CR, Faulds D. Gefitinib. Drugs. 2002;62(15):2237-48; discussion 2249-50. Review. PubMed PMID: 12381224.

603: Morris C. The role of EGFR-directed therapy in the treatment of breast cancer. Breast Cancer Res Treat. 2002 Oct;75 Suppl 1:S51-5; discussion S57-9. Review. PubMed PMID: 12353824.

604: Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 2002;7 Suppl 4:31-9. Review. PubMed PMID:

12202786.

605: Natale RB, Zaretsky SL. ZD1839 (Iressa): what's in it for the patient? Oncologist. 2002;7 Suppl 4:25-30. Review. PubMed PMID: 12202785.

606: Ranson M. ZD1839 (Iressa): for more than just non-small cell lung cancer. Oncologist. 2002;7 Suppl 4:16-24. Review. PubMed PMID: 12202784.

607: Herbst RS, Kies MS. ZD1839 (Iressa) in non-small cell lung cancer. Oncologist. 2002;7 Suppl 4:9-15. Review. PubMed PMID: 12202783.

608: Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 2002;7 Suppl 4:2-8. Review. PubMed PMID: 12202782.

609: Sánchez De Cos Escuín J. [New therapeutic targets and strategies in lung cancer]. Arch Bronconeumol. 2002 Aug;38(8):386-91. Review. Spanish. PubMed PMID:

12199921.

610: Bayes M, Rabasseda X, Prous JR. Gateways to Clinical Trials. June 2002. Methods Find Exp Clin Pharmacol. 2002 Jun;24(5):291-327. Review. PubMed PMID: 12168506.

611: Arteaga CL, Moulder SL, Yakes FM. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol. 2002 Jun;29(3 Suppl 11):4-10. Review. PubMed PMID: 12138392.

612: Wakeling AE. Epidermal growth factor receptor tyrosine kinase inhibitors. Curr Opin Pharmacol. 2002 Aug;2(4):382-7. Review. PubMed PMID: 12127870.

613: Gabriel B, Fischer DC, Kieback DG. Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies. Onkologie. 2002 Jun;25(3):240-7. Review. PubMed PMID: 12119458.

614: Ranson M, Mansoor W, Jayson G. ZD1839 (IRESSA): a selective EGFR-TK inhibitor. Expert Rev Anticancer Ther. 2002 Apr;2(2):161-8. Review. PubMed PMID:

12113238.

615: Kudoh S, Yamauchi S. [Future trends in anticancer chemotherapy]. Nippon Rinsho. 2002 May;60 Suppl 5:726-32. Review. Japanese. PubMed PMID: 12101772.

616: Kawate N. [Latest therapeutic strategy for stage IV non-small cell lung cancer]. Nippon Rinsho. 2002 May;60 Suppl 5:490-3. Review. Japanese. PubMed PMID: 12101720.

617: Yoh K, Kubota K. [New treatment strategy for stage III non-small-cell lung cancer]. Nippon Rinsho. 2002 May;60 Suppl 5:485-9. Review. Japanese. PubMed PMID: 12101719.

618: Nakagawa K. [ZD1839]. Nippon Rinsho. 2002 May;60 Suppl 5:378-83. Review. Japanese. PubMed PMID: 12101693.

619: Grünwald V, Hidalgo M. The epidermal growth factor receptor: a new target for anticancer therapy. Curr Probl Cancer. 2002 May-Jun;26(3):109-64. Review. PubMed PMID: 12085086.

620: Daud A, Munster P, Munster P, Spriggs DR. New drugs in gynecologic cancer. Curr Treat Options Oncol. 2001 Apr;2(2):119-28. Review. PubMed PMID: 12057130.

621: Baselga J, Albanell J. Targeting epidermal growth factor receptor in lung cancer. Curr Oncol Rep. 2002 Jul;4(4):317-24. Review. PubMed PMID: 12044241.

622: Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer

therapy. Expert Opin Investig Drugs. 2002 Jun;11(6):837-49. Review. PubMed PMID:

12036427.

623: Fukuoka M. [Progress in diagnosis and treatment of lung cancer]. Nippon Naika Gakkai Zasshi. 2002 Mar 20;91 Suppl:15-22. Review. Japanese. PubMed PMID: 11989256.

624: Wakeling AE, Nicholson RI, Gee JM. Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin Cancer Res. 2001 Dec;7(12 Suppl):4350s-4355s; discussion 4411s-4412s. Review. PubMed PMID: 11916224.

625: Tamura T. [Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors]. Nippon Geka Gakkai Zasshi. 2002 Feb;103(2):233-6. Review. Japanese. PubMed PMID: 11904986.

626: Kobayashi K. [Non surgical new treatment modalities for lung cancer]. Nippon Geka Gakkai Zasshi. 2002 Feb;103(2):217. Review. Japanese. PubMed PMID: 11904982.

627: Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA Jr. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002 Feb;29(1 Suppl 4):37-46. Review. PubMed PMID: 11894012.

628: Arteaga CL, Chinratanalab W, Carter MB. Inhibitors of HER2/neu (erbB-2) signal transduction. Semin Oncol. 2001 Dec;28(6 Suppl 18):30-5. Review. PubMed PMID: 11774203.

629: Slichenmyer WJ, Fry DW. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol. 2001 Oct;28(5 Suppl 16):67-79. Review. PubMed PMID: 11706398.

630: Albanell J, Rojo F, Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol. 2001 Oct;28(5 Suppl 16):56-66. Review. PubMed PMID: 11706397.

631: Harari PM, Huang SM. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol. 2001 Oct;11(4):281-9. Review. PubMed PMID: 11677653.

632: Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol. 2001 Nov;13(6):491-8. Review. PubMed PMID: 11673690.

633: Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001 Oct;7(10):2958-70. Review. PubMed PMID: 11595683.

634: Barton J, Blackledge G, Wakeling A. Growth factors and their receptors: new

targets for prostate cancer therapy. Urology. 2001 Aug;58(2 Suppl 1):114-22. Review. PubMed PMID: 11502465.

635: Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000 Dec 27;19(56):6550-65. Review. PubMed PMID: 11426640.

636: Nakagawa K. [Tyrosine kinase inhibitors--solid cancers]. Gan To Kagaku Ryoho. 2001 May;28(5):608-13. Review. Japanese. PubMed PMID: 11383208.

637: Ono M, Kuwano M. [Tumor angiogenesis and tumor angiogenesis inhibitors]. Gan To Kagaku Ryoho. 2001 May;28(5):584-90. Review. Japanese. PubMed PMID: 11383205.

638: Meric JB, Faivre S, Monnerat C, Adi Vago N, Le Chevalier T, Armand JP, Raymond E. [Zd 1839 "Iressa"]. Bull Cancer. 2000 Dec;87(12):873-6. Review. French. PubMed PMID: 11174115.

639: Ryan PD, Chabner BA. On receptor inhibitors and chemotherapy. Clin Cancer Res. 2000 Dec;6(12):4607-9. Review. PubMed PMID: 11156209.

640: Baselga J, Averbuch SD. ZD1839 ('Iressa') as an anticancer agent. Drugs. 2000;60 Suppl 1:33-40; discussion 41-2. Review. PubMed PMID: 11129170.

641: Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs. 2000;60 Suppl 1:25-32; discussion 41-2.